ID

DB00187|APRD00954|DB00171|

名称

Esmolol

描述

Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine.

cas号

81147-92-4

唯一标识码

MDY902UXSR

状态

solid

组

approved,

指示

For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.

药效学

作用机制

Similar to other beta-blockers, esmolol blocks the agonistic effect of the sympathetic neurotransmitters by competing for receptor binding sites. Because it predominantly blocks the beta-1 receptors in cardiac tissue, it is said to be cardioselective. In general, so-called cardioselective beta-blockers are relatively cardioselective; at lower doses they block beta-1 receptors only but begin to block beta-2 receptors as the dose increases. At therapeutic dosages, esmolol does not have intrinsic sympathomimetic activity (ISA) or membrane-stabilizing (quinidine-like) activity. Antiarrhythmic activity is due to blockade of adrenergic stimulation of cardiac pacemaker potentials. In the Vaughan Williams classification of antiarrhythmics, beta-blockers are considered to be class II agents.

毒性

Symptoms of overdose include cardiac arrest, bradycardia, hypotension, electromechanical dissociation and loss of consciousness.

代谢

Esmolol undergoes rapid hydrolysis of ester linkage which is catalyzed by esterases found in the cytosol of red blood cells (RBCs). The plasma cholinersterases or RBC membrane acetylcholinesterases are not involved in this metabolic reaction. Metabolism of the drug occurs mainly in RBCs to form a free acid metabolite (with 1/1500 the activity of esmolol) and methanol.

吸收

Rapidly absorbed, steady-state blood levels for dosages from 50-300 µg/kg/min (0.05-0.3 mg/kg/mm) are obtained within five minutes.

半衰期

Rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. The acid metabolite has an elimination half-life of about 3.7 hours.

分类

description:This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
direct-parent:Phenol ethers
kingdom:Organic compounds
superclass:Benzenoids
class:Phenol ethers
subclass:
alternative-parent:1,2-aminoalcohols
alternative-parent:Alkyl aryl ethers
alternative-parent:Amino acids and derivatives
alternative-parent:Carbonyl compounds
alternative-parent:Dialkylamines
alternative-parent:Fatty acid esters
alternative-parent:Hydrocarbon derivatives
alternative-parent:Methyl esters
alternative-parent:Monocarboxylic acids and derivatives
alternative-parent:Organic oxides
alternative-parent:Organopnictogen compounds
alternative-parent:Phenoxy compounds
alternative-parent:Secondary alcohols
substituent:1,2-aminoalcohol
substituent:Alcohol
substituent:Alkyl aryl ether
substituent:Amine
substituent:Amino acid or derivatives
substituent:Aromatic homomonocyclic compound
substituent:Carbonyl group
substituent:Carboxylic acid derivative
substituent:Carboxylic acid ester
substituent:Ether
substituent:Fatty acid ester
substituent:Fatty acyl
substituent:Hydrocarbon derivative
substituent:Methyl ester
substituent:Monocarboxylic acid or derivatives
substituent:Monocyclic benzene moiety
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Phenol ether
substituent:Phenoxy compound
substituent:Secondary alcohol
substituent:Secondary aliphatic amine
substituent:Secondary amine

消除途径

Consistent with the high rate of blood-based metabolism of esmolol hydrochloride, less than 2% of the drug is excreted unchanged in the urine. The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate. Excretion of the acid metabolite is significantly decreased in patients with renal disease, with the elimination half-life increased to about ten-fold that of normals, and plasma levels considerably elevated.

种类

Adrenergic Agents
D018663
Adrenergic Antagonists
D018674
Adrenergic beta-1 Receptor Antagonists
D058671
Adrenergic beta-Antagonists
D000319
Agents causing hyperkalemia

Alcohols
D000438
Amines
D000588
Amino Alcohols
D000605
Antiarrhythmic agents
D000889
Antihypertensive Agents
D000959
Antihypertensive Agents Indicated for Hypertension

Beta Blocking Agents, Selective

Beta-Blockers (Beta1 Selective)

Bradycardia-Causing Agents

Cytochrome P-450 CYP2D6 Substrates

Cytochrome P-450 Substrates

Hypotensive Agents

Neurotransmitter Agents
D018377
Potential QTc-Prolonging Agents

Propanols
D020005
QTc Prolonging Agents

盐类

DBSALT000586Esmolol hydrochlorideV05260LC8D81161-17-3GEKNCWBANDDJJL-UHFFFAOYSA-N331.835331.155036032

蛋白质结合

55% bound to human plasma protein, while the acid metabolite is 10% bound.

清除

* 20 L/kg/hr [Men]

同义词

language:english; code:; name;(±)-esmolol
language:english; code:; name;(±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
language:english; code:; name;3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester
language:english; code:inn; name;Esmolol
language:english; code:; name;Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate
language:english; code:; name;methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate

国际品牌

配送量

产品

name:Brevibloc
labeller:Baxter Healthcare Corporation
ndc-id:
ndc-product-code:10019-025
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-03-02
ended-marketing-on:2007-03-02
dosage-form:Injection, solution, concentrate
strength:250 mg/1mL
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Brevibloc
labeller:Baxter Healthcare Corporation
ndc-id:
ndc-product-code:10019-085
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-03-02
ended-marketing-on:2007-03-02
dosage-form:Injection
strength:20 mg/1mL
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Brevibloc
labeller:General Injectables & Vaccines
ndc-id:
ndc-product-code:52584-115
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-07-01
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Brevibloc
labeller:Baxter Healthcare Corporation
ndc-id:
ndc-product-code:10019-668
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Injection
strength:20 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Brevibloc
labeller:Baxter Healthcare Corporation
ndc-id:
ndc-product-code:10019-672
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Brevibloc
labeller:Baxter Healthcare Corporation
ndc-id:
ndc-product-code:10019-666
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Injection
strength:20 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Brevibloc
labeller:Baxter Healthcare Corporation
ndc-id:
ndc-product-code:10019-670
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Brevibloc
labeller:Baxter Healthcare Corporation
ndc-id:
ndc-product-code:10019-115
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Brevibloc
labeller:Baxter Healthcare Corporation
ndc-id:
ndc-product-code:10019-075
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Injection
strength:20 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Brevibloc
labeller:Baxter Healthcare Corporation
ndc-id:
ndc-product-code:10019-055
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Brevibloc Injection 10mg/ml
labeller:Baxter Laboratories
ndc-id:
ndc-product-code:
dpd-id:02188880
ema-product-code:
ema-ma-number:
started-marketing-on:1996-08-16
ended-marketing-on:
dosage-form:Solution
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Brevibloc Injection 250mg/ml
labeller:Baxter Laboratories
ndc-id:
ndc-product-code:
dpd-id:02188864
ema-product-code:
ema-ma-number:
started-marketing-on:1997-01-17
ended-marketing-on:2007-06-27
dosage-form:Liquid
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Brevibloc Liq IV 10mg/ml
labeller:Ohmeda Pharmaceutical Products, Division Of Boc Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02053179
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:1996-09-26
dosage-form:Liquid
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Brevibloc Liq IV 250mg/ml
labeller:Ohmeda Pharmaceutical Products, Division Of Boc Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02053101
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:1997-08-25
dosage-form:Liquid
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Brevibloc Premixed Injection
labeller:Baxter Laboratories
ndc-id:
ndc-product-code:
dpd-id:02309238
ema-product-code:
ema-ma-number:
started-marketing-on:2008-09-12
ended-marketing-on:
dosage-form:Solution
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Esmolol
labeller:General Injectables & Vaccines
ndc-id:
ndc-product-code:52584-017
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-04-01
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:West Ward Pharmaceutical
ndc-id:
ndc-product-code:0641-2965
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Mylan Teoranta
ndc-id:
ndc-product-code:63286-0182
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-09
ended-marketing-on:2013-05-10
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076474
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Bedford Pharmaceuticals
ndc-id:
ndc-product-code:55390-340
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-03-03
ended-marketing-on:2012-01-31
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076323
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Bedford Pharmaceuticals
ndc-id:
ndc-product-code:55390-062
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-10-04
ended-marketing-on:2014-09-30
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076323
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:General Injectables & Vaccines
ndc-id:
ndc-product-code:52584-652
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2012-06-13
ended-marketing-on:2017-07-01
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076573
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:AuroMedics Pharma LLC
ndc-id:
ndc-product-code:55150-194
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-23
ended-marketing-on:
dosage-form:Injection, solution
strength:100 mg/10mL
route:Intravenous
fda-application-number:ANDA205520
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Mylan Institutional LLC
ndc-id:
ndc-product-code:67457-182
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-05-29
ended-marketing-on:
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076474
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:General Injectables and Vaccines, Inc.
ndc-id:
ndc-product-code:52584-194
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-09-20
ended-marketing-on:
dosage-form:Injection, solution
strength:100 mg/10mL
route:Intravenous
fda-application-number:ANDA205520
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Baxter Healthcare Corporation
ndc-id:
ndc-product-code:10019-120
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Sagent Pharmaceuticals
ndc-id:
ndc-product-code:25021-308
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-15
ended-marketing-on:
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA207107
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Sagent Pharmaceuticals
ndc-id:
ndc-product-code:25021-309
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-07-15
ended-marketing-on:
dosage-form:Injection, solution
strength:20 mg/1mL
route:Intravenous
fda-application-number:ANDA207107
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Gland Pharma Limited
ndc-id:
ndc-product-code:68083-211
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-08-19
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA208538
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:General Injectables and Vaccines, Inc.
ndc-id:
ndc-product-code:52584-049
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-09
ended-marketing-on:2019-08-31
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076474
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-4512
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-23
ended-marketing-on:
dosage-form:Injection, solution
strength:100 mg/10mL
route:Intravenous
fda-application-number:ANDA205520
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:WG Critical Care, LLC
ndc-id:
ndc-product-code:44567-811
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-12-04
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA205703
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:WG Critical Care, LLC
ndc-id:
ndc-product-code:44567-812
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-12-04
ended-marketing-on:
dosage-form:Injection
strength:20 mg/1mL
route:Intravenous
fda-application-number:NDA205703
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-4699
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-05-29
ended-marketing-on:
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076474
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Sagent Pharmaceuticals
ndc-id:
ndc-product-code:25021-314
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-01-15
ended-marketing-on:
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA208538
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Fresenius Kabi USA, LLC
ndc-id:
ndc-product-code:63323-652
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-11-30
ended-marketing-on:
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076573
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Medical Purchasing Solutions, Llc
ndc-id:
ndc-product-code:71872-7136
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Medical Purchasing Solutions, Llc
ndc-id:
ndc-product-code:71872-7049
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-23
ended-marketing-on:
dosage-form:Injection, solution
strength:100 mg/10mL
route:Intravenous
fda-application-number:ANDA205520
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:HF Acquisition Co LLC, DBA HealthFirst
ndc-id:
ndc-product-code:51662-1444
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-12-22
ended-marketing-on:
dosage-form:Injection, solution
strength:100 mg/10mL
route:Intravenous
fda-application-number:ANDA205520
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:HF Acquisition Co LLC, DBA HealthFirst
ndc-id:
ndc-product-code:51662-1371
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-12-08
ended-marketing-on:
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076573
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:HF Acquisition Co LLC, DBA HealthFirst
ndc-id:
ndc-product-code:51662-1427
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-12-21
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:HF Acquisition Co LLC, DBA HealthFirst
ndc-id:
ndc-product-code:51662-1322
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-10-19
ended-marketing-on:
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076474
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:AMERICAN REGENT, INC.
ndc-id:
ndc-product-code:0517-1810
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-01-01
ended-marketing-on:2016-02-01
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA201126
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-2888
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1986-12-31
ended-marketing-on:2019-04-30
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:NDA019386
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride
labeller:General Injectables & Vaccines, Inc
ndc-id:
ndc-product-code:52584-062
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-08-01
ended-marketing-on:2017-01-18
dosage-form:Injection, solution
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA076323
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride In Sodium Chloride
labeller:Mylan Institutional LLC
ndc-id:
ndc-product-code:67457-658
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-09-04
ended-marketing-on:
dosage-form:Injection
strength:20 mg/1mL
route:Intravenous
fda-application-number:ANDA206608
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Esmolol Hydrochloride In Sodium Chloride
labeller:Mylan Institutional LLC
ndc-id:
ndc-product-code:67457-657
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-09-04
ended-marketing-on:
dosage-form:Injection
strength:10 mg/1mL
route:Intravenous
fda-application-number:ANDA206608
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC

混合物

name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol
ingredients:Esmolol
name:Brevibloc
ingredients:Esmolol
name:Brevibloc
ingredients:Esmolol
name:Esmolol Hydrochloride In Sodium Chloride
ingredients:Esmolol
name:Esmolol Hydrochloride In Sodium Chloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Brevibloc
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Brevibloc
ingredients:Esmolol
name:Brevibloc
ingredients:Esmolol
name:Brevibloc
ingredients:Esmolol
name:Brevibloc
ingredients:Esmolol
name:Brevibloc
ingredients:Esmolol
name:Brevibloc
ingredients:Esmolol
name:Brevibloc
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Esmolol Hydrochloride
ingredients:Esmolol
name:Brevibloc Injection 10mg/ml
ingredients:Esmolol
name:Brevibloc Premixed Injection
ingredients:Esmolol
name:Brevibloc Liq IV 250mg/ml
ingredients:Esmolol
name:Brevibloc Liq IV 10mg/ml
ingredients:Esmolol
name:Brevibloc Injection 250mg/ml
ingredients:Esmolol

包装者

name:APP Pharmaceuticals
url:http://www.apppharma.com
name:Baxter International Inc.
url:http://www.baxter.com
name:Bedford Labs
url:http://www.bedfordlabs.com
name:Ben Venue Laboratories Inc.
url:http://www.benvenue.com
name:Bioniche Pharma
url:http://www.bionichepharmausa.com
name:Bristol-Myers Squibb Co.
url:http://www.bms.com
name:Draxis Specialty Pharmaceuticals Inc.
url:http://www.draxispharma.com
name:General Injectables and Vaccines Inc.
url:http://www.giv.com
name:Paddock Labs
url:http://www.paddocklabs.com

生产者

generic:否; url:; name;Baxter healthcare corp anesthesia critical care
generic:是; url:; name;App pharmaceuticals llc
generic:是; url:; name;Bedford laboratories
generic:是; url:; name;Bioniche pharma usa llc

价格

Esmolol hcl 10 mg/ml vial
1.26(单位：USD）
ml
Brevibloc 20 mg/ml iv bag
1.54(单位：USD）
ml
Brevibloc 10 mg/ml vial
2.21(单位：USD）
ml
Brevibloc 250 mg/ml ampul
13.21(单位：USD）
ml

受影响的生物体

Humans and other mammals

剂量

form:Injection
route:Intravenous
strength:20 mg/1mL
form:Injection, solution
route:Parenteral
strength:100 MG/10ML
form:Injection, solution, concentrate
route:Intravenous
strength:250 mg/1mL
form:Solution
route:Parenteral
strength:100 mg/10ml
form:Injection, solution
route:Intravenous
strength:10 mg/ml
form:Solution
route:Intravenous
strength:
form:Solution
route:Intravenous
strength:100 mg
form:Liquid
route:Intravenous
strength:
form:Injection
route:Intravenous
strength:10 mg/ml
form:Injection, solution
route:
strength:20 MG/ML
form:Injection, solution
route:
strength:100 mg/10mL
form:Solution
route:Intravenous
strength:10 mg/ml
form:Injection, solution
route:Intravenous
strength:20 mg/ml
form:Solution, concentrate
route:Intravenous
strength:10 mg
form:Solution, concentrate
route:Intravenous
strength:250 mg
form:Injection, powder, for solution
route:Parenteral
strength:2500 mg
form:Injection, solution
route:Parenteral
strength:10 mg/ml
form:Injection
route:Intravenous
strength:10 mg/1mL
form:Injection, solution
route:Intravenous
strength:10 mg/1mL
form:Injection, solution
route:Intravenous
strength:100 mg/10mL
form:Injection, solution
route:Intravenous
strength:20 mg/1mL
form:Injection
route:Intravenous
strength:2500 mg/250ml

atc代码

Beta blocking agents, selective
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
CARDIOVASCULAR SYSTEM

fda标签

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00187.pdf?1265922738

专利

number:2410446
country:Canada
approved:2008-08-26
expires:2022-01-02
pediatric-extension:否
number:6528540
country:United States
approved:2003-03-04
expires:2021-07-12
pediatric-extension:是
number:6310094
country:United States
approved:2001-10-30
expires:2021-07-12
pediatric-extension:是
number:8835505
country:United States
approved:2014-09-16
expires:2033-03-15
pediatric-extension:否
number:8829054
country:United States
approved:2014-09-09
expires:2033-03-15
pediatric-extension:否

食物相互作用

药物相互作用

DB00476
The risk or severity of orthostatic hypotension and syncope can be increased when Esmolol is combined with Duloxetine.
DB01235
The risk or severity of hypotension and orthostatic hypotension can be increased when Esmolol is combined with Levodopa.
DB00734
Esmolol may increase the hypotensive activities of Risperidone.
DB09063
Esmolol may increase the bradycardic activities of Ceritinib.
DB09083
Esmolol may increase the bradycardic activities of Ivabradine.
DB08877
Ruxolitinib may increase the bradycardic activities of Esmolol.
DB00346
Alfuzosin may increase the hypotensive activities of Esmolol.
DB01143
Esmolol may increase the hypotensive activities of Amifostine.
DB01119
Diazoxide may increase the hypotensive activities of Esmolol.
DB00422
Methylphenidate may decrease the antihypertensive activities of Esmolol.
DB06701
Dexmethylphenidate may decrease the antihypertensive activities of Esmolol.
DB08935
Esmolol may increase the hypotensive activities of Obinutuzumab.
DB00806
Pentoxifylline may increase the hypotensive activities of Esmolol.
DB00073
Esmolol may increase the hypotensive activities of Rituximab.
DB00035
Desmopressin may decrease the antihypertensive activities of Esmolol.
DB00315
Zolmitriptan may decrease the antihypertensive activities of Esmolol.
DB00561
Doxapram may decrease the antihypertensive activities of Esmolol.
DB00669
Sumatriptan may decrease the antihypertensive activities of Esmolol.
DB00830
Phenmetrazine may decrease the antihypertensive activities of Esmolol.
DB00952
Naratriptan may decrease the antihypertensive activities of Esmolol.
DB00953
Rizatriptan may decrease the antihypertensive activities of Esmolol.
DB00988
Dopamine may decrease the antihypertensive activities of Esmolol.
DB00998
Frovatriptan may decrease the antihypertensive activities of Esmolol.
DB01126
Dutasteride may decrease the antihypertensive activities of Esmolol.
DB01216
Finasteride may decrease the antihypertensive activities of Esmolol.
DB01392
Yohimbine may decrease the antihypertensive activities of Esmolol.
DB02032
Epicaptopril may decrease the antihypertensive activities of Esmolol.
DB04581
1-benzylimidazole may decrease the antihypertensive activities of Esmolol.
DB04836
Amineptine may decrease the antihypertensive activities of Esmolol.
DB04908
Flibanserin may decrease the antihypertensive activities of Esmolol.
DB05562
Naluzotan may decrease the antihypertensive activities of Esmolol.
DB06690
Nitrous oxide may decrease the antihypertensive activities of Esmolol.
DB08810
Cinitapride may decrease the antihypertensive activities of Esmolol.
DB08841
Tyramine may decrease the antihypertensive activities of Esmolol.
DB08954
Ifenprodil may decrease the antihypertensive activities of Esmolol.
DB08996
Dimetacrine may decrease the antihypertensive activities of Esmolol.
DB09205
Moxisylyte may decrease the antihypertensive activities of Esmolol.
DB09289
Tianeptine may decrease the antihypertensive activities of Esmolol.
DB09307
Oxaprotiline may decrease the antihypertensive activities of Esmolol.
DB11481
Atipamezole may decrease the antihypertensive activities of Esmolol.
DB11755
Tetrahydrocannabivarin may decrease the antihypertensive activities of Esmolol.
DB12361
Piclozotan may decrease the antihypertensive activities of Esmolol.
DB12371
Siponimod may decrease the antihypertensive activities of Esmolol.
DB12551
Idazoxan may decrease the antihypertensive activities of Esmolol.
DB13064
Tramazoline may decrease the antihypertensive activities of Esmolol.
DB13114
Amitriptylinoxide may decrease the antihypertensive activities of Esmolol.
DB13225
Dibenzepin may decrease the antihypertensive activities of Esmolol.
DB13246
Quinupramine may decrease the antihypertensive activities of Esmolol.
DB13323
Trichloroethylene may decrease the antihypertensive activities of Esmolol.
DB13341
Fenozolone may decrease the antihypertensive activities of Esmolol.
DB13384
Melitracen may decrease the antihypertensive activities of Esmolol.
DB13411
Lofepramine may decrease the antihypertensive activities of Esmolol.
DB13453
Xenon may decrease the antihypertensive activities of Esmolol.
DB13496
Iprindole may decrease the antihypertensive activities of Esmolol.
DB13510
Buflomedil may decrease the antihypertensive activities of Esmolol.
DB13598
Diethyl ether may decrease the antihypertensive activities of Esmolol.
DB13782
Imipramine oxide may decrease the antihypertensive activities of Esmolol.
DB13852
Mefenorex may decrease the antihypertensive activities of Esmolol.
DB14010
5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Esmolol.
DB14231
Quinoline Yellow WS may decrease the antihypertensive activities of Esmolol.
DB14754
Solriamfetol may decrease the antihypertensive activities of Esmolol.
DB00708
Sufentanil may decrease the antihypertensive activities of Esmolol.
DB00899
Remifentanil may decrease the antihypertensive activities of Esmolol.
DB01159
Halothane may decrease the antihypertensive activities of Esmolol.
DB12930
Opipramol may decrease the antihypertensive activities of Esmolol.
DB15685
Selpercatinib may decrease the antihypertensive activities of Esmolol.
DB15965
Naxitamab may decrease the antihypertensive activities of Esmolol.
DB01118
The therapeutic efficacy of Esmolol can be increased when used in combination with Amiodarone.
DB00297
The serum concentration of Bupivacaine can be increased when it is combined with Esmolol.
DB00975
Dipyridamole may increase the bradycardic activities of Esmolol.
DB00280
Disopyramide may increase the bradycardic activities of Esmolol.
DB04855
Dronedarone may increase the bradycardic activities of Esmolol.
DB08868
Esmolol may increase the bradycardic activities of Fingolimod.
DB08976
The risk or severity of adverse effects can be increased when Esmolol is combined with Floctafenine.
DB00961
The serum concentration of Mepivacaine can be increased when it is combined with Esmolol.
DB06709
Esmolol may increase the bronchoconstrictory activities of Methacholine.
DB00211
The therapeutic efficacy of Midodrine can be decreased when used in combination with Esmolol.
DB01115
The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Esmolol.
DB01182
The risk or severity of adverse effects can be increased when Propafenone is combined with Esmolol.
DB08896
Regorafenib may increase the bradycardic activities of Esmolol.
DB00206
Reserpine may increase the hypotensive activities of Esmolol.
DB01089
Deserpidine may increase the hypotensive activities of Esmolol.
DB01170
Guanethidine may increase the hypotensive activities of Esmolol.
DB00989
Esmolol may increase the bradycardic activities of Rivastigmine.
DB09220
Nicorandil may increase the hypotensive activities of Esmolol.
DB09282
Molsidomine may increase the hypotensive activities of Esmolol.
DB00030
Esmolol may increase the hypoglycemic activities of Insulin human.
DB00046
Esmolol may increase the hypoglycemic activities of Insulin lispro.
DB00047
Esmolol may increase the hypoglycemic activities of Insulin glargine.
DB00071
Esmolol may increase the hypoglycemic activities of Insulin pork.
DB01306
Esmolol may increase the hypoglycemic activities of Insulin aspart.
DB01307
Esmolol may increase the hypoglycemic activities of Insulin detemir.
DB01309
Esmolol may increase the hypoglycemic activities of Insulin glulisine.
DB05115
Esmolol may increase the hypoglycemic activities of NN344.
DB09456
Esmolol may increase the hypoglycemic activities of Insulin beef.
DB09564
Esmolol may increase the hypoglycemic activities of Insulin degludec.
DB11567
Esmolol may increase the hypoglycemic activities of Insulin peglispro.
DB11568
Esmolol may increase the hypoglycemic activities of Insulin tregopil.
DB11564
Esmolol may increase the hypoglycemic activities of Insulin argine.
DB00287
Esmolol may increase the hypotensive activities of Travoprost.
DB00869
Esmolol may increase the hypotensive activities of Dorzolamide.
DB00905
Esmolol may increase the hypotensive activities of Bimatoprost.
DB06826
Esmolol may increase the hypotensive activities of Unoprostone.
DB00212
Esmolol may increase the hypotensive activities of Remikiren.
DB00214
Esmolol may increase the hypotensive activities of Torasemide.
DB00226
Esmolol may increase the hypotensive activities of Guanadrel.
DB00310
Esmolol may increase the hypotensive activities of Chlorthalidone.
DB00325
Esmolol may increase the hypotensive activities of Nitroprusside.
DB00350
Esmolol may increase the hypotensive activities of Minoxidil.
DB00524
Esmolol may increase the hypotensive activities of Metolazone.
DB00559
Esmolol may increase the hypotensive activities of Bosentan.
DB00616
Esmolol may increase the hypotensive activities of Candoxatril.
DB00657
Esmolol may increase the hypotensive activities of Mecamylamine.
DB00727
Esmolol may increase the hypotensive activities of Nitroglycerin.
DB00765
Esmolol may increase the hypotensive activities of Metyrosine.
DB00785
Esmolol may increase the hypotensive activities of Cryptenamine.
DB00800
Esmolol may increase the hypotensive activities of Fenoldopam.
DB01090
Esmolol may increase the hypotensive activities of Pentolinium.
DB01116
Esmolol may increase the hypotensive activities of Trimethaphan.
DB01275
Esmolol may increase the hypotensive activities of Hydralazine.
DB04831
Esmolol may increase the hypotensive activities of Tienilic acid.
DB04840
Esmolol may increase the hypotensive activities of Debrisoquine.
DB06268
Esmolol may increase the hypotensive activities of Sitaxentan.
DB06403
Esmolol may increase the hypotensive activities of Ambrisentan.
DB06445
Esmolol may increase the hypotensive activities of Diethylnorspermine.
DB06762
Esmolol may increase the hypotensive activities of Pinacidil.
DB07767
Esmolol may increase the hypotensive activities of Ferulic acid.
DB08931
Esmolol may increase the hypotensive activities of Riociguat.
DB08932
Esmolol may increase the hypotensive activities of Macitentan.
DB08960
Esmolol may increase the hypotensive activities of Hexamethonium.
DB09363
Esmolol may increase the hypotensive activities of Rauwolfia serpentina root.
DB11362
Esmolol may increase the hypotensive activities of Selexipag.
DB11720
Esmolol may increase the hypotensive activities of Angiotensin 1-7.
DB12054
Esmolol may increase the hypotensive activities of BQ-123.
DB12465
Esmolol may increase the hypotensive activities of Ketanserin.
DB12945
Esmolol may increase the hypotensive activities of Dihydralazine.
DB13211
Esmolol may increase the hypotensive activities of Guanoxan.
DB13374
Esmolol may increase the hypotensive activities of Vincamine.
DB13400
Esmolol may increase the hypotensive activities of Linsidomine.
DB13410
Esmolol may increase the hypotensive activities of Guanoxabenz.
DB13429
Esmolol may increase the hypotensive activities of Tolonidine.
DB13435
Esmolol may increase the hypotensive activities of Endralazine.
DB13452
Esmolol may increase the hypotensive activities of Cadralazine.
DB13575
Esmolol may increase the hypotensive activities of Bietaserpine.
DB13604
Esmolol may increase the hypotensive activities of Guanazodine.
DB13631
Esmolol may increase the hypotensive activities of Methoserpidine.
DB13779
Esmolol may increase the hypotensive activities of Guanoclor.
DB13801
Esmolol may increase the hypotensive activities of Muzolimine.
DB13803
Esmolol may increase the hypotensive activities of Xipamide.
DB14094
Esmolol may increase the hypotensive activities of Tocopherylquinone.
DB00695
Furosemide may increase the hypotensive activities of Esmolol.
DB00178
Ramipril may increase the hypotensive activities of Esmolol.
DB00790
Esmolol may increase the hypotensive activities of Perindopril.
DB09237
Esmolol may increase the hypotensive activities of Levamlodipine.
DB00484
Brimonidine may increase the antihypertensive activities of Esmolol.
DB00184
The risk or severity of adverse effects can be increased when Esmolol is combined with Nicotine.
DB00185
The risk or severity of adverse effects can be increased when Esmolol is combined with Cevimeline.
DB00411
The risk or severity of adverse effects can be increased when Esmolol is combined with Carbamoylcholine.
DB01019
The risk or severity of adverse effects can be increased when Esmolol is combined with Bethanechol.
DB01085
The risk or severity of adverse effects can be increased when Esmolol is combined with Pilocarpine.
DB01273
The risk or severity of adverse effects can be increased when Esmolol is combined with Varenicline.
DB03128
The risk or severity of adverse effects can be increased when Esmolol is combined with Acetylcholine.
DB04365
The risk or severity of adverse effects can be increased when Esmolol is combined with Arecoline.
DB05137
The risk or severity of adverse effects can be increased when Esmolol is combined with Lobeline.
DB05152
The risk or severity of adverse effects can be increased when Esmolol is combined with NGX267.
DB05708
The risk or severity of adverse effects can be increased when Esmolol is combined with GTS-21.
DB07720
The risk or severity of adverse effects can be increased when Esmolol is combined with Epibatidine.
DB15357
The risk or severity of adverse effects can be increased when Esmolol is combined with Xanomeline.
DB00372
The serum concentration of Esmolol can be increased when it is combined with Thiethylperazine.
DB00420
The serum concentration of Esmolol can be increased when it is combined with Promazine.
DB00433
The serum concentration of Esmolol can be increased when it is combined with Prochlorperazine.
DB00508
The serum concentration of Esmolol can be increased when it is combined with Triflupromazine.
DB00623
The serum concentration of Esmolol can be increased when it is combined with Fluphenazine.
DB00831
The serum concentration of Esmolol can be increased when it is combined with Trifluoperazine.
DB00850
The serum concentration of Esmolol can be increased when it is combined with Perphenazine.
DB00933
The serum concentration of Esmolol can be increased when it is combined with Mesoridazine.
DB01063
The serum concentration of Esmolol can be increased when it is combined with Acetophenazine.
DB01069
The serum concentration of Esmolol can be increased when it is combined with Promethazine.
DB01246
The serum concentration of Esmolol can be increased when it is combined with Alimemazine.
DB01608
The serum concentration of Esmolol can be increased when it is combined with Periciazine.
DB01614
The serum concentration of Esmolol can be increased when it is combined with Acepromazine.
DB01615
The serum concentration of Esmolol can be increased when it is combined with Aceprometazine.
DB01621
The serum concentration of Esmolol can be increased when it is combined with Pipotiazine.
DB01622
The serum concentration of Esmolol can be increased when it is combined with Thioproperazine.
DB05687
The serum concentration of Esmolol can be increased when it is combined with BL-1020.
DB09000
The serum concentration of Esmolol can be increased when it is combined with Cyamemazine.
DB09241
The serum concentration of Esmolol can be increased when it is combined with Methylene blue.
DB11540
The serum concentration of Esmolol can be increased when it is combined with Propiopromazine.
DB12710
The serum concentration of Esmolol can be increased when it is combined with Perazine.
DB13213
The serum concentration of Esmolol can be increased when it is combined with Butaperazine.
DB13382
The serum concentration of Esmolol can be increased when it is combined with Chlorproethazine.
DB13420
The serum concentration of Esmolol can be increased when it is combined with Thiazinam.
DB13784
The serum concentration of Esmolol can be increased when it is combined with Dixyrazine.
DB14651
The serum concentration of Esmolol can be increased when it is combined with Perphenazine enanthate.
DB01092
Esmolol may increase the bradycardic activities of Ouabain.
DB12843
Esmolol may increase the bradycardic activities of Oleandrin.
DB13307
Esmolol may increase the bradycardic activities of Proscillaridin.
DB13467
Esmolol may increase the bradycardic activities of Lanatoside C.
DB13537
Esmolol may increase the bradycardic activities of Gitoformate.
DB13756
Esmolol may increase the bradycardic activities of Peruvoside.
DB00281
The serum concentration of Lidocaine can be increased when it is combined with Esmolol.
DB00159
Icosapent may decrease the antihypertensive activities of Esmolol.
DB00244
Mesalazine may decrease the antihypertensive activities of Esmolol.
DB00328
Indomethacin may decrease the antihypertensive activities of Esmolol.
DB00461
Nabumetone may decrease the antihypertensive activities of Esmolol.
DB00465
Ketorolac may decrease the antihypertensive activities of Esmolol.
DB00469
Tenoxicam may decrease the antihypertensive activities of Esmolol.
DB00482
Celecoxib may decrease the antihypertensive activities of Esmolol.
DB00500
Tolmetin may decrease the antihypertensive activities of Esmolol.
DB00533
Rofecoxib may decrease the antihypertensive activities of Esmolol.
DB00554
Piroxicam may decrease the antihypertensive activities of Esmolol.
DB00573
Fenoprofen may decrease the antihypertensive activities of Esmolol.
DB00580
Valdecoxib may decrease the antihypertensive activities of Esmolol.
DB00586
Diclofenac may decrease the antihypertensive activities of Esmolol.
DB00605
Sulindac may decrease the antihypertensive activities of Esmolol.
DB00712
Flurbiprofen may decrease the antihypertensive activities of Esmolol.
DB00749
Etodolac may decrease the antihypertensive activities of Esmolol.
DB00784
Mefenamic acid may decrease the antihypertensive activities of Esmolol.
DB00788
Naproxen may decrease the antihypertensive activities of Esmolol.
DB00795
Sulfasalazine may decrease the antihypertensive activities of Esmolol.
DB00812
Phenylbutazone may decrease the antihypertensive activities of Esmolol.
DB00814
Meloxicam may decrease the antihypertensive activities of Esmolol.
DB00821
Carprofen may decrease the antihypertensive activities of Esmolol.
DB00861
Diflunisal may decrease the antihypertensive activities of Esmolol.
DB00936
Salicylic acid may decrease the antihypertensive activities of Esmolol.
DB00939
Meclofenamic acid may decrease the antihypertensive activities of Esmolol.
DB00945
Acetylsalicylic acid may decrease the antihypertensive activities of Esmolol.
DB00991
Oxaprozin may decrease the antihypertensive activities of Esmolol.
DB01009
Ketoprofen may decrease the antihypertensive activities of Esmolol.
DB01014
Balsalazide may decrease the antihypertensive activities of Esmolol.
DB01050
Ibuprofen may decrease the antihypertensive activities of Esmolol.
DB01250
Olsalazine may decrease the antihypertensive activities of Esmolol.
DB01283
Lumiracoxib may decrease the antihypertensive activities of Esmolol.
DB01397
Magnesium salicylate may decrease the antihypertensive activities of Esmolol.
DB01399
Salsalate may decrease the antihypertensive activities of Esmolol.
DB01401
Choline magnesium trisalicylate may decrease the antihypertensive activities of Esmolol.
DB01419
Antrafenine may decrease the antihypertensive activities of Esmolol.
DB01424
Aminophenazone may decrease the antihypertensive activities of Esmolol.
DB01435
Antipyrine may decrease the antihypertensive activities of Esmolol.
DB01600
Tiaprofenic acid may decrease the antihypertensive activities of Esmolol.
DB01628
Etoricoxib may decrease the antihypertensive activities of Esmolol.
DB02224
Taxifolin may decrease the antihypertensive activities of Esmolol.
DB03585
Oxyphenbutazone may decrease the antihypertensive activities of Esmolol.
DB04725
Licofelone may decrease the antihypertensive activities of Esmolol.
DB04743
Nimesulide may decrease the antihypertensive activities of Esmolol.
DB04812
Benoxaprofen may decrease the antihypertensive activities of Esmolol.
DB04817
Metamizole may decrease the antihypertensive activities of Esmolol.
DB04828
Zomepirac may decrease the antihypertensive activities of Esmolol.
DB05095
Cimicoxib may decrease the antihypertensive activities of Esmolol.
DB06725
Lornoxicam may decrease the antihypertensive activities of Esmolol.
DB06736
Aceclofenac may decrease the antihypertensive activities of Esmolol.
DB06737
Zaltoprofen may decrease the antihypertensive activities of Esmolol.
DB07402
Azapropazone may decrease the antihypertensive activities of Esmolol.
DB08439
Parecoxib may decrease the antihypertensive activities of Esmolol.
DB08797
Salicylamide may decrease the antihypertensive activities of Esmolol.
DB08940
Kebuzone may decrease the antihypertensive activities of Esmolol.
DB08942
Isoxicam may decrease the antihypertensive activities of Esmolol.
DB08951
Indoprofen may decrease the antihypertensive activities of Esmolol.
DB08955
Ibuproxam may decrease the antihypertensive activities of Esmolol.
DB08981
Fenbufen may decrease the antihypertensive activities of Esmolol.
DB08984
Etofenamate may decrease the antihypertensive activities of Esmolol.
DB08991
Epirizole may decrease the antihypertensive activities of Esmolol.
DB09084
Benzydamine may decrease the antihypertensive activities of Esmolol.
DB09213
Dexibuprofen may decrease the antihypertensive activities of Esmolol.
DB09214
Dexketoprofen may decrease the antihypertensive activities of Esmolol.
DB09215
Droxicam may decrease the antihypertensive activities of Esmolol.
DB09216
Tolfenamic acid may decrease the antihypertensive activities of Esmolol.
DB09217
Firocoxib may decrease the antihypertensive activities of Esmolol.
DB09218
Clonixin may decrease the antihypertensive activities of Esmolol.
DB09285
Morniflumate may decrease the antihypertensive activities of Esmolol.
DB09288
Propacetamol may decrease the antihypertensive activities of Esmolol.
DB09295
Talniflumate may decrease the antihypertensive activities of Esmolol.
DB11455
Robenacoxib may decrease the antihypertensive activities of Esmolol.
DB11466
Tepoxalin may decrease the antihypertensive activities of Esmolol.
DB11518
Flunixin may decrease the antihypertensive activities of Esmolol.
DB12399
Polmacoxib may decrease the antihypertensive activities of Esmolol.
DB12445
Nitroaspirin may decrease the antihypertensive activities of Esmolol.
DB12545
Indobufen may decrease the antihypertensive activities of Esmolol.
DB12610
Ebselen may decrease the antihypertensive activities of Esmolol.
DB13001
Tinoridine may decrease the antihypertensive activities of Esmolol.
DB13167
Alclofenac may decrease the antihypertensive activities of Esmolol.
DB13217
Fentiazac may decrease the antihypertensive activities of Esmolol.
DB13232
Suxibuzone may decrease the antihypertensive activities of Esmolol.
DB13286
Bumadizone may decrease the antihypertensive activities of Esmolol.
DB13314
Alminoprofen may decrease the antihypertensive activities of Esmolol.
DB13371
Difenpiramide may decrease the antihypertensive activities of Esmolol.
DB13407
Nifenazone may decrease the antihypertensive activities of Esmolol.
DB13432
Lonazolac may decrease the antihypertensive activities of Esmolol.
DB13481
Tenidap may decrease the antihypertensive activities of Esmolol.
DB13524
Propyphenazone may decrease the antihypertensive activities of Esmolol.
DB13527
Proglumetacin may decrease the antihypertensive activities of Esmolol.
DB13538
Guacetisal may decrease the antihypertensive activities of Esmolol.
DB13544
Ethenzamide may decrease the antihypertensive activities of Esmolol.
DB13612
Carbaspirin calcium may decrease the antihypertensive activities of Esmolol.
DB13629
Mofebutazone may decrease the antihypertensive activities of Esmolol.
DB13649
Proquazone may decrease the antihypertensive activities of Esmolol.
DB13657
Benorilate may decrease the antihypertensive activities of Esmolol.
DB13722
Pirprofen may decrease the antihypertensive activities of Esmolol.
DB13783
Acemetacin may decrease the antihypertensive activities of Esmolol.
DB13860
Imidazole salicylate may decrease the antihypertensive activities of Esmolol.
DB14059
SC-236 may decrease the antihypertensive activities of Esmolol.
DB14060
NS-398 may decrease the antihypertensive activities of Esmolol.
DB14938
Flurbiprofen axetil may decrease the antihypertensive activities of Esmolol.
DB09212
Loxoprofen may decrease the antihypertensive activities of Esmolol.
DB00414
Esmolol may increase the hypoglycemic activities of Acetohexamide.
DB00672
Esmolol may increase the hypoglycemic activities of Chlorpropamide.
DB00839
Esmolol may increase the hypoglycemic activities of Tolazamide.
DB01016
Esmolol may increase the hypoglycemic activities of Glyburide.
DB01067
Esmolol may increase the hypoglycemic activities of Glipizide.
DB01120
Esmolol may increase the hypoglycemic activities of Gliclazide.
DB01124
Esmolol may increase the hypoglycemic activities of Tolbutamide.
DB01251
Esmolol may increase the hypoglycemic activities of Gliquidone.
DB01289
Esmolol may increase the hypoglycemic activities of Glisoxepide.
DB08962
Esmolol may increase the hypoglycemic activities of Glibornuride.
DB13406
Esmolol may increase the hypoglycemic activities of Carbutamide.
DB13675
Esmolol may increase the hypoglycemic activities of Metahexamide.
DB00203
Sildenafil may increase the antihypertensive activities of Esmolol.
DB00235
Milrinone may increase the antihypertensive activities of Esmolol.
DB00820
Tadalafil may increase the antihypertensive activities of Esmolol.
DB05266
Ibudilast may increase the antihypertensive activities of Esmolol.
DB06237
Avanafil may increase the antihypertensive activities of Esmolol.
DB06267
Udenafil may increase the antihypertensive activities of Esmolol.
DB11792
Mirodenafil may increase the antihypertensive activities of Esmolol.
DB12010
Fostamatinib may increase the antihypertensive activities of Esmolol.
DB00247
Esmolol may increase the vasoconstricting activities of Methysergide.
DB00248
Esmolol may increase the vasoconstricting activities of Cabergoline.
DB00320
Esmolol may increase the vasoconstricting activities of Dihydroergotamine.
DB00353
Esmolol may increase the vasoconstricting activities of Methylergometrine.
DB00589
Esmolol may increase the vasoconstricting activities of Lisuride.
DB00696
Esmolol may increase the vasoconstricting activities of Ergotamine.
DB00699
Esmolol may increase the vasoconstricting activities of Nicergoline.
DB01049
Esmolol may increase the vasoconstricting activities of Ergoloid mesylate.
DB04829
Esmolol may increase the vasoconstricting activities of Lysergic acid diethylamide.
DB11273
Esmolol may increase the vasoconstricting activities of Dihydroergocornine.
DB13345
Esmolol may increase the vasoconstricting activities of Dihydroergocristine.
DB13385
Esmolol may increase the vasoconstricting activities of Dihydroergocryptine.
DB13399
Esmolol may increase the vasoconstricting activities of Terguride.
DB13520
Esmolol may increase the vasoconstricting activities of Metergoline.
DB01105
The serum concentration of Esmolol can be increased when it is combined with Sibutramine.
DB01149
The serum concentration of Esmolol can be increased when it is combined with Nefazodone.
DB04832
The serum concentration of Esmolol can be increased when it is combined with Zimelidine.
DB04884
The serum concentration of Esmolol can be increased when it is combined with Dapoxetine.
DB04896
The serum concentration of Esmolol can be increased when it is combined with Milnacipran.
DB06700
The serum concentration of Esmolol can be increased when it is combined with Desvenlafaxine.
DB06731
The serum concentration of Esmolol can be increased when it is combined with Seproxetine.
DB08918
The serum concentration of Esmolol can be increased when it is combined with Levomilnacipran.
DB08953
The serum concentration of Esmolol can be increased when it is combined with Indalpine.
DB13233
The serum concentration of Esmolol can be increased when it is combined with Alaproclate.
DB01104
The serum concentration of Esmolol can be increased when it is combined with Sertraline.
DB00201
The risk or severity of adverse effects can be increased when Esmolol is combined with Caffeine.
DB00651
The risk or severity of adverse effects can be increased when Esmolol is combined with Dyphylline.
DB01223
The risk or severity of adverse effects can be increased when Esmolol is combined with Aminophylline.
DB01303
The risk or severity of adverse effects can be increased when Esmolol is combined with Oxtriphylline.
DB01412
The risk or severity of adverse effects can be increased when Esmolol is combined with Theobromine.
DB01482
The risk or severity of adverse effects can be increased when Esmolol is combined with Fenethylline.
DB01667
The risk or severity of adverse effects can be increased when Esmolol is combined with 8-azaguanine.
DB01978
The risk or severity of adverse effects can be increased when Esmolol is combined with 7,9-Dimethylguanine.
DB02134
The risk or severity of adverse effects can be increased when Esmolol is combined with Xanthine.
DB02245
The risk or severity of adverse effects can be increased when Esmolol is combined with 7-Deazaguanine.
DB02377
The risk or severity of adverse effects can be increased when Esmolol is combined with Guanine.
DB02489
The risk or severity of adverse effects can be increased when Esmolol is combined with 9-Methylguanine.
DB02568
The risk or severity of adverse effects can be increased when Esmolol is combined with Peldesine.
DB04076
The risk or severity of adverse effects can be increased when Esmolol is combined with Hypoxanthine.
DB04356
The risk or severity of adverse effects can be increased when Esmolol is combined with 9-Deazaguanine.
DB06479
The risk or severity of adverse effects can be increased when Esmolol is combined with Propentofylline.
DB06575
The risk or severity of adverse effects can be increased when Esmolol is combined with Valomaciclovir.
DB07954
The risk or severity of adverse effects can be increased when Esmolol is combined with 3-isobutyl-1-methyl-7H-xanthine.
DB08844
The risk or severity of adverse effects can be increased when Esmolol is combined with Uric acid.
DB11919
The risk or severity of adverse effects can be increased when Esmolol is combined with 6-O-benzylguanine.
DB12406
The risk or severity of adverse effects can be increased when Esmolol is combined with Lisofylline.
DB12531
The risk or severity of adverse effects can be increased when Esmolol is combined with Lobucavir.
DB12926
The risk or severity of adverse effects can be increased when Esmolol is combined with Cafedrine.
DB12927
The risk or severity of adverse effects can be increased when Esmolol is combined with Theodrenaline.
DB13203
The risk or severity of adverse effects can be increased when Esmolol is combined with Bamifylline.
DB13449
The risk or severity of adverse effects can be increased when Esmolol is combined with Proxyphylline.
DB13573
The risk or severity of adverse effects can be increased when Esmolol is combined with Acefylline.
DB13592
The risk or severity of adverse effects can be increased when Esmolol is combined with Etamiphylline.
DB13634
The risk or severity of adverse effects can be increased when Esmolol is combined with Pentifylline.
DB13812
The risk or severity of adverse effects can be increased when Esmolol is combined with Bufylline.
DB14018
The risk or severity of adverse effects can be increased when Esmolol is combined with Bromotheophylline.
DB14029
The risk or severity of adverse effects can be increased when Esmolol is combined with Furafylline.
DB14132
The risk or severity of adverse effects can be increased when Esmolol is combined with 8-chlorotheophylline.
DB00521
Esmolol may increase the arrhythmogenic activities of Carteolol.
DB01214
Esmolol may increase the arrhythmogenic activities of Metipranolol.
DB00680
Moricizine may increase the arrhythmogenic activities of Esmolol.
DB00390
Esmolol may increase the arrhythmogenic activities of Digoxin.
DB00511
Esmolol may increase the arrhythmogenic activities of Acetyldigitoxin.
DB01078
Esmolol may increase the arrhythmogenic activities of Deslanoside.
DB01396
Esmolol may increase the arrhythmogenic activities of Digitoxin.
DB13240
Esmolol may increase the arrhythmogenic activities of Cymarin.
DB13401
Esmolol may increase the arrhythmogenic activities of Metildigoxin.
DB13691
Esmolol may increase the arrhythmogenic activities of Acetyldigoxin.
DB00222
Esmolol may increase the arrhythmogenic activities of Glimepiride.
DB01056
Esmolol may increase the arrhythmogenic activities of Tocainide.
DB11699
Esmolol may increase the arrhythmogenic activities of Tropisetron.
DB12704
Esmolol may increase the arrhythmogenic activities of Spiradoline.
DB13635
Esmolol may increase the arrhythmogenic activities of Tiracizine.
DB13645
Esmolol may increase the arrhythmogenic activities of Ethacizine.
DB13718
Esmolol may increase the arrhythmogenic activities of Hydroquinine.
DB13746
Esmolol may increase the arrhythmogenic activities of Bioallethrin.
DB13863
Esmolol may increase the arrhythmogenic activities of Fosfructose.
DB15300
Esmolol may increase the arrhythmogenic activities of Hydroquinidine.
DB15366
SOR-C13 may increase the arrhythmogenic activities of Esmolol.
DB00195
Esmolol may increase the arrhythmogenic activities of Betaxolol.
DB00571
Esmolol may increase the arrhythmogenic activities of Propranolol.
DB00572
Esmolol may increase the arrhythmogenic activities of Atropine.
DB00640
Esmolol may increase the arrhythmogenic activities of Adenosine.
DB00922
Esmolol may increase the arrhythmogenic activities of Levosimendan.
DB01193
Esmolol may increase the arrhythmogenic activities of Acebutolol.
DB01580
Esmolol may increase the arrhythmogenic activities of Oxprenolol.
DB04957
Esmolol may increase the arrhythmogenic activities of Azimilide.
DB06200
Esmolol may increase the arrhythmogenic activities of Tedisamil.
DB08952
Esmolol may increase the arrhythmogenic activities of Indenolol.
DB09224
Esmolol may increase the arrhythmogenic activities of Melperone.
DB12286
Esmolol may increase the arrhythmogenic activities of Simendan.
DB13546
Esmolol may increase the arrhythmogenic activities of Nizofenone.
DB13652
Esmolol may increase the arrhythmogenic activities of Bunaftine.
DB13653
Esmolol may increase the arrhythmogenic activities of Lorcainide.
DB00204
Esmolol may increase the arrhythmogenic activities of Dofetilide.
DB00308
Esmolol may increase the arrhythmogenic activities of Ibutilide.
DB00908
Esmolol may increase the arrhythmogenic activities of Quinidine.
DB00335
Esmolol may increase the arrhythmogenic activities of Atenolol.
DB00678
Esmolol may increase the arrhythmogenic activities of Losartan.
DB00866
Esmolol may increase the arrhythmogenic activities of Alprenolol.
DB01203
Esmolol may increase the arrhythmogenic activities of Nadolol.
DB01297
Esmolol may increase the arrhythmogenic activities of Practolol.
DB08808
Esmolol may increase the arrhythmogenic activities of Bupranolol.
DB11770
Esmolol may increase the arrhythmogenic activities of Talinolol.
DB12212
Esmolol may increase the arrhythmogenic activities of Landiolol.
DB13775
Esmolol may increase the arrhythmogenic activities of Tertatolol.
DB14207
Esmolol may increase the arrhythmogenic activities of Fosinoprilat.
DB04846
Esmolol may increase the arrhythmogenic activities of Celiprolol.
DB04861
Esmolol may increase the arrhythmogenic activities of Nebivolol.
DB11785
Esmolol may increase the arrhythmogenic activities of Anisodamine.
DB00424
Esmolol may increase the arrhythmogenic activities of Hyoscyamine.
DB01228
Esmolol may increase the arrhythmogenic activities of Encainide.
DB01426
Esmolol may increase the arrhythmogenic activities of Ajmaline.
DB06468
Esmolol may increase the arrhythmogenic activities of Cariporide.
DB12712
Esmolol may increase the arrhythmogenic activities of Pilsicainide.
DB13358
Esmolol may increase the arrhythmogenic activities of Cibenzoline.
DB13555
Esmolol may increase the arrhythmogenic activities of Prajmaline.
DB13651
Esmolol may increase the arrhythmogenic activities of Lorajmine.
DB01158
Esmolol may increase the arrhythmogenic activities of Bretylium.
DB03322
Esmolol may increase the arrhythmogenic activities of Dexpropranolol.
DB12766
Esmolol may increase the arrhythmogenic activities of Cicletanine.
DB06217
Vernakalant may increase the arrhythmogenic activities of Esmolol.
DB06727
Sparteine may increase the arrhythmogenic activities of Esmolol.
DB00379
Esmolol may increase the arrhythmogenic activities of Mexiletine.
DB01429
Esmolol may increase the arrhythmogenic activities of Aprindine.
DB00489
Esmolol may increase the arrhythmogenic activities of Sotalol.
DB01035
Esmolol may increase the arrhythmogenic activities of Procainamide.
DB01195
Esmolol may increase the arrhythmogenic activities of Flecainide.
DB00230
Esmolol may increase the arrhythmogenic activities of Pregabalin.
DB00825
Esmolol may increase the arrhythmogenic activities of Levomenthol.
DB00270
The risk or severity of bradycardia can be increased when Isradipine is combined with Esmolol.
DB00347
The risk or severity of bradycardia can be increased when Trimethadione is combined with Esmolol.
DB00381
The risk or severity of bradycardia can be increased when Amlodipine is combined with Esmolol.
DB00401
The risk or severity of bradycardia can be increased when Nisoldipine is combined with Esmolol.
DB00555
The risk or severity of bradycardia can be increased when Lamotrigine is combined with Esmolol.
DB00593
The risk or severity of bradycardia can be increased when Ethosuximide is combined with Esmolol.
DB00653
The risk or severity of bradycardia can be increased when Magnesium sulfate is combined with Esmolol.
DB00909
The risk or severity of bradycardia can be increased when Zonisamide is combined with Esmolol.
DB01023
The risk or severity of bradycardia can be increased when Felodipine is combined with Esmolol.
DB01054
The risk or severity of bradycardia can be increased when Nitrendipine is combined with Esmolol.
DB04838
The risk or severity of bradycardia can be increased when Cyclandelate is combined with Esmolol.
DB04841
The risk or severity of bradycardia can be increased when Flunarizine is combined with Esmolol.
DB04920
The risk or severity of bradycardia can be increased when Clevidipine is combined with Esmolol.
DB05246
The risk or severity of bradycardia can be increased when Methsuximide is combined with Esmolol.
DB05885
The risk or severity of bradycardia can be increased when Seletracetam is combined with Esmolol.
DB06283
The risk or severity of bradycardia can be increased when Ziconotide is combined with Esmolol.
DB06446
The risk or severity of bradycardia can be increased when Dotarizine is combined with Esmolol.
DB07615
The risk or severity of bradycardia can be increased when Tranilast is combined with Esmolol.
DB08162
The risk or severity of bradycardia can be increased when Fasudil is combined with Esmolol.
DB08838
The risk or severity of bradycardia can be increased when Agmatine is combined with Esmolol.
DB09089
The risk or severity of bradycardia can be increased when Trimebutine is combined with Esmolol.
DB09090
The risk or severity of bradycardia can be increased when Pinaverium is combined with Esmolol.
DB09229
The risk or severity of bradycardia can be increased when Aranidipine is combined with Esmolol.
DB09230
The risk or severity of bradycardia can be increased when Azelnidipine is combined with Esmolol.
DB09232
The risk or severity of bradycardia can be increased when Cilnidipine is combined with Esmolol.
DB09234
The risk or severity of bradycardia can be increased when Darodipine is combined with Esmolol.
DB09235
The risk or severity of bradycardia can be increased when Efonidipine is combined with Esmolol.
DB09240
The risk or severity of bradycardia can be increased when Niludipine is combined with Esmolol.
DB11960
The risk or severity of bradycardia can be increased when Carboxyamidotriazole is combined with Esmolol.
DB12092
The risk or severity of bradycardia can be increased when Naftopidil is combined with Esmolol.
DB12093
The risk or severity of bradycardia can be increased when Tetrahydropalmatine is combined with Esmolol.
DB12131
The risk or severity of bradycardia can be increased when Vinpocetine is combined with Esmolol.
DB12923
The risk or severity of bradycardia can be increased when Gallopamil is combined with Esmolol.
DB13488
The risk or severity of bradycardia can be increased when Bencyclane is combined with Esmolol.
DB13766
The risk or severity of bradycardia can be increased when Lidoflazine is combined with Esmolol.
DB13835
The risk or severity of bradycardia can be increased when Caroverine is combined with Esmolol.
DB13950
The risk or severity of bradycardia can be increased when WIN 55212-2 is combined with Esmolol.
DB13961
The risk or severity of bradycardia can be increased when Fish oil is combined with Esmolol.
DB14064
The risk or severity of bradycardia can be increased when Emopamil is combined with Esmolol.
DB14065
The risk or severity of bradycardia can be increased when Lomerizine is combined with Esmolol.
DB14066
The risk or severity of bradycardia can be increased when Tetrandrine is combined with Esmolol.
DB14068
The risk or severity of bradycardia can be increased when Dexniguldipine is combined with Esmolol.
DB01136
The risk or severity of bradycardia can be increased when Esmolol is combined with Carvedilol.
DB09239
The risk or severity of bradycardia can be increased when Esmolol is combined with Niguldipine.
DB00343
The risk or severity of bradycardia can be increased when Esmolol is combined with Diltiazem.
DB00393
The risk or severity of bradycardia can be increased when Esmolol is combined with Nimodipine.
DB00568
The risk or severity of bradycardia can be increased when Esmolol is combined with Cinnarizine.
DB00836
The risk or severity of bradycardia can be increased when Esmolol is combined with Loperamide.
DB01388
The risk or severity of bradycardia can be increased when Esmolol is combined with Mibefradil.
DB04825
The risk or severity of bradycardia can be increased when Esmolol is combined with Prenylamine.
DB04842
The risk or severity of bradycardia can be increased when Esmolol is combined with Fluspirilene.
DB06712
The risk or severity of bradycardia can be increased when Esmolol is combined with Nilvadipine.
DB08980
The risk or severity of bradycardia can be increased when Esmolol is combined with Fendiline.
DB08992
The risk or severity of bradycardia can be increased when Esmolol is combined with Eperisone.
DB09231
The risk or severity of bradycardia can be increased when Esmolol is combined with Benidipine.
DB13500
The risk or severity of bradycardia can be increased when Esmolol is combined with Otilonium.
DB13791
The risk or severity of bradycardia can be increased when Esmolol is combined with Penfluridol.
DB14063
The risk or severity of bradycardia can be increased when Esmolol is combined with Dexverapamil.
DB01244
The risk or severity of bradycardia can be increased when Esmolol is combined with Bepridil.
DB13725
The risk or severity of bradycardia can be increased when Esmolol is combined with Terodiline.
DB06152
The risk or severity of bradycardia can be increased when Esmolol is combined with Nylidrin.
DB06694
The risk or severity of bradycardia can be increased when Esmolol is combined with Xylometazoline.
DB00528
The risk or severity of bradycardia can be increased when Esmolol is combined with Lercanidipine.
DB00334
Esmolol may increase the orthostatic hypotensive activities of Olanzapine.
DB00590
Esmolol may increase the orthostatic hypotensive activities of Doxazosin.
DB00598
Esmolol may increase the orthostatic hypotensive activities of Labetalol.
DB00692
Esmolol may increase the orthostatic hypotensive activities of Phentolamine.
DB00706
Esmolol may increase the orthostatic hypotensive activities of Tamsulosin.
DB00777
Esmolol may increase the orthostatic hypotensive activities of Propiomazine.
DB00797
Esmolol may increase the orthostatic hypotensive activities of Tolazoline.
DB00925
Esmolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.
DB01162
Esmolol may increase the orthostatic hypotensive activities of Terazosin.
DB01295
Esmolol may increase the orthostatic hypotensive activities of Bevantolol.
DB06153
Esmolol may increase the orthostatic hypotensive activities of Pizotifen.
DB06207
Esmolol may increase the orthostatic hypotensive activities of Silodosin.
DB08950
Esmolol may increase the orthostatic hypotensive activities of Indoramin.
DB09128
Esmolol may increase the orthostatic hypotensive activities of Brexpiprazole.
DB09206
Esmolol may increase the orthostatic hypotensive activities of Trimazosin.
DB12230
Esmolol may increase the orthostatic hypotensive activities of Bunazosin.
DB12278
Esmolol may increase the orthostatic hypotensive activities of Propiverine.
DB12661
Esmolol may increase the orthostatic hypotensive activities of Urapidil.
DB12752
Esmolol may increase the orthostatic hypotensive activities of Bucindolol.
DB00374
Treprostinil may increase the hypotensive activities of Esmolol.
DB01088
Iloprost may increase the hypotensive activities of Esmolol.
DB01240
Epoprostenol may increase the hypotensive activities of Esmolol.
DB14337
Salvia miltiorrhiza root may increase the hypotensive activities of Esmolol.
DB00082
Pegvisomant may increase the bradycardic activities of Esmolol.
DB00382
Tacrine may increase the bradycardic activities of Esmolol.
DB00392
Profenamine may increase the bradycardic activities of Esmolol.
DB00483
Gallamine triethiodide may increase the bradycardic activities of Esmolol.
DB00515
Cisplatin may increase the bradycardic activities of Esmolol.
DB00527
Cinchocaine may increase the bradycardic activities of Esmolol.
DB00545
Pyridostigmine may increase the bradycardic activities of Esmolol.
DB00585
Nizatidine may increase the bradycardic activities of Esmolol.
DB00674
Galantamine may increase the bradycardic activities of Esmolol.
DB00677
Isoflurophate may increase the bradycardic activities of Esmolol.
DB00711
Diethylcarbamazine may increase the bradycardic activities of Esmolol.
DB00843
Donepezil may increase the bradycardic activities of Esmolol.
DB00888
Mechlorethamine may increase the bradycardic activities of Esmolol.
DB00941
Hexafluronium may increase the bradycardic activities of Esmolol.
DB00944
Demecarium may increase the bradycardic activities of Esmolol.
DB00981
Physostigmine may increase the bradycardic activities of Esmolol.
DB01010
Edrophonium may increase the bradycardic activities of Esmolol.
DB01043
Memantine may increase the bradycardic activities of Esmolol.
DB01122
Ambenonium may increase the bradycardic activities of Esmolol.
DB01199
Tubocurarine may increase the bradycardic activities of Esmolol.
DB01221
Ketamine may increase the bradycardic activities of Esmolol.
DB01245
Decamethonium may increase the bradycardic activities of Esmolol.
DB01337
Pancuronium may increase the bradycardic activities of Esmolol.
DB01338
Pipecuronium may increase the bradycardic activities of Esmolol.
DB01381
Ginkgo biloba may increase the bradycardic activities of Esmolol.
DB01400
Neostigmine may increase the bradycardic activities of Esmolol.
DB02365
1,10-Phenanthroline may increase the bradycardic activities of Esmolol.
DB04572
Thiotepa may increase the bradycardic activities of Esmolol.
DB04864
Huperzine A may increase the bradycardic activities of Esmolol.
DB04892
Phenserine may increase the bradycardic activities of Esmolol.
DB05386
Regramostim may increase the bradycardic activities of Esmolol.
DB06692
Aprotinin may increase the bradycardic activities of Esmolol.
DB06756
Glycine betaine may increase the bradycardic activities of Esmolol.
DB06774
Capsaicin may increase the bradycardic activities of Esmolol.
DB11390
Coumaphos may increase the bradycardic activities of Esmolol.
DB11397
Dichlorvos may increase the bradycardic activities of Esmolol.
DB11412
Fenthion may increase the bradycardic activities of Esmolol.
DB11473
Metrifonate may increase the bradycardic activities of Esmolol.
DB12482
Acotiamide may increase the bradycardic activities of Esmolol.
DB13058
Methanesulfonyl Fluoride may increase the bradycardic activities of Esmolol.
DB13495
Paraoxon may increase the bradycardic activities of Esmolol.
DB13503
Tyrothricin may increase the bradycardic activities of Esmolol.
DB13668
Ipidacrine may increase the bradycardic activities of Esmolol.
DB13694
Distigmine may increase the bradycardic activities of Esmolol.
DB14031
Tretamine may increase the bradycardic activities of Esmolol.
DB15317
Posiphen may increase the bradycardic activities of Esmolol.
DB02845
Methylphosphinic Acid may increase the bradycardic activities of Esmolol.
DB00601
Linezolid may increase the hypotensive activities of Esmolol.
DB00614
Furazolidone may increase the hypotensive activities of Esmolol.
DB00721
Procaine may increase the hypotensive activities of Esmolol.
DB00780
Phenelzine may increase the hypotensive activities of Esmolol.
DB00805
Minaprine may increase the hypotensive activities of Esmolol.
DB01037
Selegiline may increase the hypotensive activities of Esmolol.
DB01168
Procarbazine may increase the hypotensive activities of Esmolol.
DB01171
Moclobemide may increase the hypotensive activities of Esmolol.
DB01247
Isocarboxazid may increase the hypotensive activities of Esmolol.
DB01367
Rasagiline may increase the hypotensive activities of Esmolol.
DB01626
Pargyline may increase the hypotensive activities of Esmolol.
DB04017
Clorgiline may increase the hypotensive activities of Esmolol.
DB04818
Iproniazid may increase the hypotensive activities of Esmolol.
DB04820
Nialamide may increase the hypotensive activities of Esmolol.
DB06654
Safinamide may increase the hypotensive activities of Esmolol.
DB08550
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Esmolol.
DB09243
Hydracarbazine may increase the hypotensive activities of Esmolol.
DB09244
Pirlindole may increase the hypotensive activities of Esmolol.
DB09245
Toloxatone may increase the hypotensive activities of Esmolol.
DB09246
Benmoxin may increase the hypotensive activities of Esmolol.
DB09248
Mebanazine may increase the hypotensive activities of Esmolol.
DB09249
Octamoxin may increase the hypotensive activities of Esmolol.
DB09250
Pheniprazine may increase the hypotensive activities of Esmolol.
DB09251
Phenoxypropazine may increase the hypotensive activities of Esmolol.
DB09252
Pivhydrazine may increase the hypotensive activities of Esmolol.
DB09253
Safrazine may increase the hypotensive activities of Esmolol.
DB09254
Caroxazone may increase the hypotensive activities of Esmolol.
DB13875
Harmaline may increase the hypotensive activities of Esmolol.
DB13876
Brofaromine may increase the hypotensive activities of Esmolol.
DB00237
Butabarbital may increase the hypotensive activities of Esmolol.
DB00241
The serum concentration of Esmolol can be decreased when it is combined with Butalbital.
DB00312
The serum concentration of Esmolol can be decreased when it is combined with Pentobarbital.
DB00418
The serum concentration of Esmolol can be decreased when it is combined with Secobarbital.
DB00474
The serum concentration of Esmolol can be decreased when it is combined with Methohexital.
DB00599
The serum concentration of Esmolol can be decreased when it is combined with Thiopental.
DB00794
The serum concentration of Esmolol can be decreased when it is combined with Primidone.
DB00849
The serum concentration of Esmolol can be decreased when it is combined with Methylphenobarbital.
DB01154
The serum concentration of Esmolol can be decreased when it is combined with Thiamylal.
DB01174
The serum concentration of Esmolol can be decreased when it is combined with Phenobarbital.
DB01351
The serum concentration of Esmolol can be decreased when it is combined with Amobarbital.
DB01355
The serum concentration of Esmolol can be decreased when it is combined with Hexobarbital.
DB01483
The serum concentration of Esmolol can be decreased when it is combined with Barbital.
DB09001
The serum concentration of Esmolol can be decreased when it is combined with Barbexaclone.
DB00007
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Leuprolide.
DB00014
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Goserelin.
DB00199
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Erythromycin.
DB00207
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Azithromycin.
DB00218
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Moxifloxacin.
DB00263
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Sulfisoxazole.
DB00391
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Sulpiride.
DB00450
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Droperidol.
DB00526
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Oxaliplatin.
DB00537
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ciprofloxacin.
DB00544
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Fluorouracil.
DB00556
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Perflutren.
DB00625
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Efavirenz.
DB00738
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Pentamidine.
DB00743
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Gadobenic acid.
DB00748
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Carbinoxamine.
DB00757
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dolasetron.
DB00778
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Roxithromycin.
DB00779
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Nalidixic acid.
DB00827
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Cinoxacin.
DB00889
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Granisetron.
DB00904
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ondansetron.
DB00967
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Desloratadine.
DB00976
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Telithromycin.
DB00978
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Lomefloxacin.
DB00985
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dimenhydrinate.
DB01113
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Papaverine.
DB01114
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Chlorpheniramine.
DB01137
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Levofloxacin.
DB01155
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Gemifloxacin.
DB01165
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ofloxacin.
DB01211
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Clarithromycin.
DB01227
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Levacetylmethadol.
DB01232
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Saquinavir.
DB01599
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Probucol.
DB02638
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Terlipressin.
DB05223
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Pracinostat.
DB05488
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Technetium Tc-99m ciprofloxacin.
DB06160
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Garenoxacin.
DB06334
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Tucidinostat.
DB06402
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Telavancin.
DB06589
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Pazopanib.
DB06600
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Nemonoxacin.
DB08799
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Antazoline.
DB08865
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Crizotinib.
DB08903
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Bedaquiline.
DB09016
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Butriptyline.
DB09078
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Lenvatinib.
DB09555
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dexchlorpheniramine maleate.
DB11640
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Amifampridine.
DB11830
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Mocetinostat.
DB11841
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Entinostat.
DB12141
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Gilteritinib.
DB12174
The risk or severity of QTc prolongation can be increased when Esmolol is combined with CUDC-101.
DB12376
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ricolinostat.
DB12523
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Mizolastine.
DB12565
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Abexinostat.
DB12877
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Oxatomide.
DB13261
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Sitafloxacin.
DB13273
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Sultopride.
DB13679
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dexchlorpheniramine.
DB14568
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ivosidenib.
DB01084
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Emedastine.
DB11718
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Encorafenib.
DB00041
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Esmolol.
DB00086
The risk or severity of adverse effects can be increased when Streptokinase is combined with Esmolol.
DB00268
The risk or severity of adverse effects can be increased when Ropinirole is combined with Esmolol.
DB00295
The risk or severity of adverse effects can be increased when Morphine is combined with Esmolol.
DB00296
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Esmolol.
DB00323
The risk or severity of adverse effects can be increased when Tolcapone is combined with Esmolol.
DB00413
The risk or severity of adverse effects can be increased when Pramipexole is combined with Esmolol.
DB00435
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Esmolol.
DB00486
The risk or severity of adverse effects can be increased when Nabilone is combined with Esmolol.
DB00631
The risk or severity of adverse effects can be increased when Clofarabine is combined with Esmolol.
DB00681
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Esmolol.
DB00755
The risk or severity of adverse effects can be increased when Tretinoin is combined with Esmolol.
DB00872
The risk or severity of adverse effects can be increased when Conivaptan is combined with Esmolol.
DB00883
The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Esmolol.
DB00887
The risk or severity of adverse effects can be increased when Bumetanide is combined with Esmolol.
DB00903
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Esmolol.
DB01002
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Esmolol.
DB01020
The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Esmolol.
DB01041
The risk or severity of adverse effects can be increased when Thalidomide is combined with Esmolol.
DB01144
The risk or severity of adverse effects can be increased when Diclofenamide is combined with Esmolol.
DB01229
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Esmolol.
DB01282
The risk or severity of adverse effects can be increased when Carbetocin is combined with Esmolol.
DB01612
The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Esmolol.
DB04899
The risk or severity of adverse effects can be increased when Nesiritide is combined with Esmolol.
DB06292
The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Esmolol.
DB09038
The risk or severity of adverse effects can be increased when Empagliflozin is combined with Esmolol.
DB09077
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Esmolol.
DB09112
The risk or severity of adverse effects can be increased when Nitrous acid is combined with Esmolol.
DB09286
The risk or severity of adverse effects can be increased when Pipamperone is combined with Esmolol.
DB09292
The risk or severity of adverse effects can be increased when Sacubitril is combined with Esmolol.
DB00703
The risk or severity of adverse effects can be increased when Methazolamide is combined with Esmolol.
DB00802
Esmolol may increase the bradycardic activities of Alfentanil.
DB00813
Esmolol may increase the bradycardic activities of Fentanyl.
DB04897
Esmolol may increase the bradycardic activities of Lucinactant.
DB06218
Esmolol may increase the bradycardic activities of Lacosamide.
DB06415
Esmolol may increase the bradycardic activities of Calfactant.
DB06761
Esmolol may increase the bradycardic activities of Beractant.
DB06791
Esmolol may increase the bradycardic activities of Lanreotide.
DB08895
Esmolol may increase the bradycardic activities of Tofacitinib.
DB09113
Esmolol may increase the bradycardic activities of Poractant alfa.
DB00215
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Citalopram.
DB00261
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Anagrelide.
DB00283
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Clemastine.
DB00313
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Valproic acid.
DB00365
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Grepafloxacin.
DB00539
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Toremifene.
DB00619
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Imatinib.
DB00685
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Trovafloxacin.
DB00834
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Mifepristone.
DB00875
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Flupentixol.
DB00907
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Cocaine.
DB01169
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Arsenic trioxide.
DB01184
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Domperidone.
DB01208
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Sparfloxacin.
DB01267
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Paliperidone.
DB01356
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Lithium cation.
DB01405
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Temafloxacin.
DB01624
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Zuclopenthixol.
DB04844
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Tetrabenazine.
DB04946
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Iloperidone.
DB05294
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Vandetanib.
DB06176
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Romidepsin.
DB06216
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Asenapine.
DB06697
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Artemether.
DB09039
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Eliglustat.
DB11730
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ribociclib.
DB11978
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Glasdegib.
DB12161
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Deutetrabenazine.
DB13074
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Macimorelin.
DB00477
The metabolism of Esmolol can be decreased when combined with Chlorpromazine.
DB12693
The metabolism of Esmolol can be decreased when combined with Ritanserin.
DB00752
The metabolism of Esmolol can be decreased when combined with Tranylcypromine.
DB00363
The metabolism of Clozapine can be decreased when combined with Esmolol.
DB00342
The metabolism of Terfenadine can be decreased when combined with Esmolol.
DB00468
The metabolism of Quinine can be decreased when combined with Esmolol.
DB04868
The metabolism of Nilotinib can be decreased when combined with Esmolol.
DB06708
The metabolism of Lumefantrine can be decreased when combined with Esmolol.
DB00608
The metabolism of Esmolol can be decreased when combined with Chloroquine.
DB01087
The metabolism of Esmolol can be decreased when combined with Primaquine.
DB00091
The metabolism of Esmolol can be decreased when combined with Cyclosporine.
DB00169
The metabolism of Esmolol can be decreased when combined with Cholecalciferol.
DB00176
The metabolism of Esmolol can be decreased when combined with Fluvoxamine.
DB00264
The metabolism of Esmolol can be decreased when combined with Metoprolol.
DB00285
The metabolism of Esmolol can be decreased when combined with Venlafaxine.
DB00349
The metabolism of Esmolol can be decreased when combined with Clobazam.
DB00496
The metabolism of Esmolol can be decreased when combined with Darifenacin.
DB00501
The metabolism of Esmolol can be decreased when combined with Cimetidine.
DB00503
The metabolism of Esmolol can be decreased when combined with Ritonavir.
DB00705
The metabolism of Esmolol can be decreased when combined with Delavirdine.
DB00857
The metabolism of Esmolol can be decreased when combined with Terbinafine.
DB00932
The metabolism of Esmolol can be decreased when combined with Tipranavir.
DB01026
The metabolism of Esmolol can be decreased when combined with Ketoconazole.
DB01074
The metabolism of Esmolol can be decreased when combined with Perhexiline.
DB01079
The metabolism of Esmolol can be decreased when combined with Tegaserod.
DB02703
The metabolism of Esmolol can be decreased when combined with Fusidic acid.
DB05812
The metabolism of Esmolol can be decreased when combined with Abiraterone.
DB06603
The metabolism of Esmolol can be decreased when combined with Panobinostat.
DB06684
The metabolism of Esmolol can be decreased when combined with Vilazodone.
DB06729
The metabolism of Esmolol can be decreased when combined with Sulfaphenazole.
DB06819
The metabolism of Esmolol can be decreased when combined with Phenylbutyric acid.
DB09238
The metabolism of Esmolol can be decreased when combined with Manidipine.
DB09291
The metabolism of Esmolol can be decreased when combined with Rolapitant.
DB11586
The metabolism of Esmolol can be decreased when combined with Asunaprevir.
DB12332
The metabolism of Esmolol can be decreased when combined with Rucaparib.
DB13174
The metabolism of Esmolol can be decreased when combined with Rhein.
DB00458
The metabolism of Imipramine can be decreased when combined with Esmolol.
DB01151
The metabolism of Desipramine can be decreased when combined with Esmolol.
DB09167
The metabolism of Dosulepin can be decreased when combined with Esmolol.
DB04871
The metabolism of Lorcaserin can be decreased when combined with Esmolol.
DB08893
The metabolism of Mirabegron can be decreased when combined with Esmolol.
DB00622
The metabolism of Esmolol can be decreased when combined with Nicardipine.
DB15982
The metabolism of Esmolol can be decreased when combined with Berotralstat.
DB00604
The metabolism of Esmolol can be decreased when combined with Cisapride.
DB00679
The metabolism of Esmolol can be decreased when combined with Thioridazine.
DB00715
The metabolism of Esmolol can be decreased when combined with Paroxetine.
DB01012
The metabolism of Esmolol can be decreased when combined with Cinacalcet.
DB01156
The metabolism of Esmolol can be decreased when combined with Bupropion.
DB01173
The metabolism of Esmolol can be decreased when combined with Orphenadrine.
DB01218
The metabolism of Esmolol can be decreased when combined with Halofantrine.
DB01403
The metabolism of Esmolol can be decreased when combined with Methotrimeprazine.
DB06595
The metabolism of Esmolol can be decreased when combined with Midostaurin.
DB08909
The metabolism of Esmolol can be decreased when combined with Glycerol phenylbutyrate.
DB00358
The risk or severity of QTc prolongation can be decreased when Mefloquine is combined with Esmolol.
DB00613
The risk or severity of QTc prolongation can be decreased when Amodiaquine is combined with Esmolol.
DB01611
The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Esmolol.
DB01033
The therapeutic efficacy of Mercaptopurine can be decreased when used in combination with Esmolol.
DB15122
The therapeutic efficacy of PCS-499 can be decreased when used in combination with Esmolol.
DB00177
The risk or severity of hyperkalemia can be increased when Valsartan is combined with Esmolol.
DB00202
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Succinylcholine.
DB00275
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Olmesartan.
DB00384
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Triamterene.
DB00407
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Ardeparin.
DB00421
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Spironolactone.
DB00440
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Trimethoprim.
DB00492
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Fosinopril.
DB00519
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Trandolapril.
DB00542
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Benazepril.
DB00584
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Enalapril.
DB00594
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Amiloride.
DB00698
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Nitrofurantoin.
DB00700
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Eplerenone.
DB00722
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Lisinopril.
DB00742
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Mannitol.
DB00796
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Candesartan cilexetil.
DB00876
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Eprosartan.
DB00881
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Quinapril.
DB00886
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Omapatrilat.
DB00960
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Pindolol.
DB00966
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Telmisartan.
DB01029
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Irbesartan.
DB01109
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Heparin.
DB01180
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Rescinnamine.
DB01197
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Captopril.
DB01219
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Dantrolene.
DB01225
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Enoxaparin.
DB01340
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Cilazapril.
DB01342
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Forasartan.
DB01347
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Saprisartan.
DB01348
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Spirapril.
DB01349
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Tasosartan.
DB01359
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Penbutolol.
DB01395
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Drospirenone.
DB02968
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Penicillin G Acyl-Serine.
DB06212
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Tolvaptan.
DB06271
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Sulodexide.
DB06726
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Bufuralol.
DB06754
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Danaparoid.
DB06763
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Saralasin.
DB06767
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Ammonium chloride.
DB06779
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Dalteparin.
DB06822
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Tinzaparin.
DB08807
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Bopindolol.
DB08813
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Nadroparin.
DB08822
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Azilsartan medoxomil.
DB08836
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Temocapril.
DB08907
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Canagliflozin.
DB09015
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Canrenoic acid.
DB09026
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Aliskiren.
DB09204
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Arotinolol.
DB09258
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Bemiparin.
DB09259
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Reviparin.
DB09260
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Parnaparin.
DB09261
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Certoparin.
DB09279
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Fimasartan.
DB09351
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Levobetaxolol.
DB09477
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Enalaprilat.
DB11783
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Imidapril.
DB12097
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Mannitol busulfan.
DB12221
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Canrenone.
DB13166
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Zofenopril.
DB13312
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Delapril.
DB13443
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Esatenolol.
DB13508
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Cloranolol.
DB13530
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Mepindolol.
DB13757
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Epanolol.
DB13919
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Candesartan.
DB14125
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Benazeprilat.
DB14208
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Ramiprilat.
DB14213
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Perindoprilat.
DB14217
The risk or severity of hyperkalemia can be increased when Esmolol is combined with Quinaprilat.
DB10349
The risk of a hypersensitivity reaction to Paspalum notatum pollen is increased when it is combined with Esmolol.
DB10351
The risk of a hypersensitivity reaction to Cynodon dactylon pollen is increased when it is combined with Esmolol.
DB10353
The risk of a hypersensitivity reaction to Poa annua pollen is increased when it is combined with Esmolol.
DB10365
The risk of a hypersensitivity reaction to Sorghum halepense pollen is increased when it is combined with Esmolol.
DB10366
The risk of a hypersensitivity reaction to Poa pratensis pollen is increased when it is combined with Esmolol.
DB10370
The risk of a hypersensitivity reaction to Festuca pratensis pollen is increased when it is combined with Esmolol.
DB10379
The risk of a hypersensitivity reaction to Dactylis glomerata pollen is increased when it is combined with Esmolol.
DB10389
The risk of a hypersensitivity reaction to Lolium perenne pollen is increased when it is combined with Esmolol.
DB10394
The risk of a hypersensitivity reaction to Phleum pratense pollen is increased when it is combined with Esmolol.
DB10395
The risk of a hypersensitivity reaction to Holcus lanatus pollen is increased when it is combined with Esmolol.
DB10403
The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Esmolol.
DB10404
The risk of a hypersensitivity reaction to Anthoxanthum odoratum pollen is increased when it is combined with Esmolol.
DB10489
The risk of a hypersensitivity reaction to Elymus repens pollen is increased when it is combined with Esmolol.
DB10494
The risk of a hypersensitivity reaction to Distichlis spicata pollen is increased when it is combined with Esmolol.
DB10713
The risk of a hypersensitivity reaction to Poa compressa pollen is increased when it is combined with Esmolol.
DB10714
The risk of a hypersensitivity reaction to Phalaris arundinacea pollen is increased when it is combined with Esmolol.
DB10715
The risk of a hypersensitivity reaction to Bouteloua gracilis pollen is increased when it is combined with Esmolol.
DB10716
The risk of a hypersensitivity reaction to Urochloa mutica pollen is increased when it is combined with Esmolol.
DB10717
The risk of a hypersensitivity reaction to Secale cereale pollen is increased when it is combined with Esmolol.
DB10719
The risk of a hypersensitivity reaction to Pascopyrum smithii pollen is increased when it is combined with Esmolol.
DB10836
The risk of a hypersensitivity reaction to Bromus secalinus pollen is increased when it is combined with Esmolol.
DB10879
The risk of a hypersensitivity reaction to Arrhenatherum elatius pollen is increased when it is combined with Esmolol.
DB10949
The risk of a hypersensitivity reaction to Koeleria macrantha pollen is increased when it is combined with Esmolol.
DB10962
The risk of a hypersensitivity reaction to Agrostis stolonifera pollen is increased when it is combined with Esmolol.
DB10963
The risk of a hypersensitivity reaction to Phalaris minor pollen is increased when it is combined with Esmolol.
DB10964
The risk of a hypersensitivity reaction to Lolium perenne subsp. multiflorum pollen is increased when it is combined with Esmolol.
DB10966
The risk of a hypersensitivity reaction to Sorghum bicolor subsp. drummondii pollen is increased when it is combined with Esmolol.
DB01045
The metabolism of Esmolol can be increased when combined with Rifampicin.
DB01201
The metabolism of Esmolol can be increased when combined with Rifapentine.
DB01220
The metabolism of Esmolol can be increased when combined with Rifaximin.
DB11753
The metabolism of Esmolol can be increased when combined with Rifamycin.
DB15213
The metabolism of Esmolol can be increased when combined with 25-desacetylrifapentine.
DB08881
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Vemurafenib.
DB09236
Esmolol may increase the hypotensive activities of Lacidipine.
DB00898
Ethanol may increase the hypotensive activities of Esmolol.
DB09227
Esmolol may increase the antihypertensive activities of Barnidipine.
DB11637
Esmolol may increase the QTc-prolonging activities of Delamanid.
DB13967
The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Esmolol.
DB00217
The therapeutic efficacy of Bethanidine can be decreased when used in combination with Esmolol.
DB00221
The therapeutic efficacy of Isoetharine can be decreased when used in combination with Esmolol.
DB00292
The therapeutic efficacy of Etomidate can be decreased when used in combination with Esmolol.
DB00368
The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Esmolol.
DB00388
The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Esmolol.
DB00397
The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Esmolol.
DB00610
The therapeutic efficacy of Metaraminol can be decreased when used in combination with Esmolol.
DB00629
The therapeutic efficacy of Guanabenz can be decreased when used in combination with Esmolol.
DB00633
The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Esmolol.
DB00668
The therapeutic efficacy of Epinephrine can be decreased when used in combination with Esmolol.
DB00697
The therapeutic efficacy of Tizanidine can be decreased when used in combination with Esmolol.
DB00723
The therapeutic efficacy of Methoxamine can be decreased when used in combination with Esmolol.
DB00816
The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Esmolol.
DB00841
The therapeutic efficacy of Dobutamine can be decreased when used in combination with Esmolol.
DB00867
The therapeutic efficacy of Ritodrine can be decreased when used in combination with Esmolol.
DB00871
The therapeutic efficacy of Terbutaline can be decreased when used in combination with Esmolol.
DB00901
The therapeutic efficacy of Bitolterol can be decreased when used in combination with Esmolol.
DB00935
The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Esmolol.
DB00938
The therapeutic efficacy of Salmeterol can be decreased when used in combination with Esmolol.
DB00968
The therapeutic efficacy of Methyldopa can be decreased when used in combination with Esmolol.
DB00983
The therapeutic efficacy of Formoterol can be decreased when used in combination with Esmolol.
DB01001
The therapeutic efficacy of Salbutamol can be decreased when used in combination with Esmolol.
DB01018
The therapeutic efficacy of Guanfacine can be decreased when used in combination with Esmolol.
DB01064
The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Esmolol.
DB01102
The therapeutic efficacy of Arbutamine can be decreased when used in combination with Esmolol.
DB01186
The therapeutic efficacy of Pergolide can be decreased when used in combination with Esmolol.
DB01200
The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Esmolol.
DB01253
The therapeutic efficacy of Ergometrine can be decreased when used in combination with Esmolol.
DB01274
The therapeutic efficacy of Arformoterol can be decreased when used in combination with Esmolol.
DB01288
The therapeutic efficacy of Fenoterol can be decreased when used in combination with Esmolol.
DB01291
The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Esmolol.
DB01363
The therapeutic efficacy of Ephedra sinica root can be decreased when used in combination with Esmolol.
DB01364
The therapeutic efficacy of Ephedrine can be decreased when used in combination with Esmolol.
DB01366
The therapeutic efficacy of Procaterol can be decreased when used in combination with Esmolol.
DB01407
The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Esmolol.
DB01408
The therapeutic efficacy of Bambuterol can be decreased when used in combination with Esmolol.
DB01472
The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Esmolol.
DB01537
The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Esmolol.
DB01579
The therapeutic efficacy of Phendimetrazine can be decreased when used in combination with Esmolol.
DB04948
The therapeutic efficacy of Lofexidine can be decreased when used in combination with Esmolol.
DB05039
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Esmolol.
DB05395
The therapeutic efficacy of Amibegron can be decreased when used in combination with Esmolol.
DB06190
The therapeutic efficacy of Solabegron can be decreased when used in combination with Esmolol.
DB06262
The therapeutic efficacy of Droxidopa can be decreased when used in combination with Esmolol.
DB06706
The therapeutic efficacy of Isometheptene can be decreased when used in combination with Esmolol.
DB06707
The therapeutic efficacy of Levonordefrin can be decreased when used in combination with Esmolol.
DB06711
The therapeutic efficacy of Naphazoline can be decreased when used in combination with Esmolol.
DB06764
The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Esmolol.
DB06814
The therapeutic efficacy of Protokylol can be decreased when used in combination with Esmolol.
DB08925
The therapeutic efficacy of Adrafinil can be decreased when used in combination with Esmolol.
DB08941
The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Esmolol.
DB08957
The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Esmolol.
DB08985
The therapeutic efficacy of Etilefrine can be decreased when used in combination with Esmolol.
DB09080
The therapeutic efficacy of Olodaterol can be decreased when used in combination with Esmolol.
DB09082
The therapeutic efficacy of Vilanterol can be decreased when used in combination with Esmolol.
DB09202
The therapeutic efficacy of Cirazoline can be decreased when used in combination with Esmolol.
DB09203
The therapeutic efficacy of Synephrine can be decreased when used in combination with Esmolol.
DB09242
The therapeutic efficacy of Moxonidine can be decreased when used in combination with Esmolol.
DB09273
The therapeutic efficacy of Doxofylline can be decreased when used in combination with Esmolol.
DB11124
The therapeutic efficacy of Racepinephrine can be decreased when used in combination with Esmolol.
DB11278
The therapeutic efficacy of DL-Methylephedrine can be decreased when used in combination with Esmolol.
DB11373
The therapeutic efficacy of Amitraz can be decreased when used in combination with Esmolol.
DB11428
The therapeutic efficacy of Medetomidine can be decreased when used in combination with Esmolol.
DB11477
The therapeutic efficacy of Xylazine can be decreased when used in combination with Esmolol.
DB11541
The therapeutic efficacy of Ractopamine can be decreased when used in combination with Esmolol.
DB11543
The therapeutic efficacy of Romifidine can be decreased when used in combination with Esmolol.
DB11556
The therapeutic efficacy of Detomidine can be decreased when used in combination with Esmolol.
DB11587
The therapeutic efficacy of Etafedrine can be decreased when used in combination with Esmolol.
DB11738
The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Esmolol.
DB11871
The therapeutic efficacy of PF-00610355 can be decreased when used in combination with Esmolol.
DB12100
The therapeutic efficacy of Abediterol can be decreased when used in combination with Esmolol.
DB12248
The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Esmolol.
DB12313
The therapeutic efficacy of Dopexamine can be decreased when used in combination with Esmolol.
DB12526
The therapeutic efficacy of Batefenterol can be decreased when used in combination with Esmolol.
DB12779
The therapeutic efficacy of Higenamine can be decreased when used in combination with Esmolol.
DB12846
The therapeutic efficacy of Reproterol can be decreased when used in combination with Esmolol.
DB13139
The therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Esmolol.
DB13251
The therapeutic efficacy of Octopamine can be decreased when used in combination with Esmolol.
DB13378
The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Esmolol.
DB13398
The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Esmolol.
DB13559
The therapeutic efficacy of Rimiterol can be decreased when used in combination with Esmolol.
DB13692
The therapeutic efficacy of Tretoquinol can be decreased when used in combination with Esmolol.
DB13777
The therapeutic efficacy of Prenalterol can be decreased when used in combination with Esmolol.
DB13781
The therapeutic efficacy of Xamoterol can be decreased when used in combination with Esmolol.
DB14752
The therapeutic efficacy of Racephedrine can be decreased when used in combination with Esmolol.
DB14547
The therapeutic efficacy of Chloride ion can be decreased when used in combination with Esmolol.
DB00862
The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Esmolol.
DB00196
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Fluconazole.
DB00691
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Moexipril.
DB00864
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Tacrolimus.
DB01015
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Sulfamethoxazole.
DB00107
The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Esmolol.
DB00245
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Benzatropine.
DB00289
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Atomoxetine.
DB00341
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Cetirizine.
DB00354
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Buclizine.
DB00366
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Doxylamine.
DB00370
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Mirtazapine.
DB00405
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dexbrompheniramine.
DB00427
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Triprolidine.
DB00434
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Cyproheptadine.
DB00467
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Enoxacin.
DB00487
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Pefloxacin.
DB00529
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Foscarnet.
DB00582
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Voriconazole.
DB00710
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ibandronate.
DB00719
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Azatadine.
DB00817
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Rosoxacin.
DB00822
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Disulfiram.
DB00835
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Brompheniramine.
DB00915
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Amantadine.
DB00916
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Metronidazole.
DB00920
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ketotifen.
DB00927
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Famotidine.
DB00934
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Maprotiline.
DB00949
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Felbamate.
DB01036
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Tolterodine.
DB01044
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Gatifloxacin.
DB01059
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Norfloxacin.
DB01072
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Atazanavir.
DB01106
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Levocabastine.
DB01166
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Cilostazol.
DB01176
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Cyclizine.
DB01239
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Chlorprothixene.
DB01254
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dasatinib.
DB01259
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Lapatinib.
DB01263
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Posaconazole.
DB01268
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Sunitinib.
DB01591
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Solifenacin.
DB01620
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Pheniramine.
DB02546
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Vorinostat.
DB04576
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Fleroxacin.
DB04695
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Farnesyl thiopyrophosphate.
DB04953
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ezogabine.
DB05465
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Tandutinib.
DB06282
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Levocetirizine.
DB06288
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Amisulpride.
DB06663
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Pasireotide.
DB06699
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Degarelix.
DB06719
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Buserelin.
DB06788
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Histrelin.
DB06825
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Triptorelin.
DB07780
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Farnesyl diphosphate.
DB07841
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Geranylgeranyl diphosphate.
DB08815
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Lurasidone.
DB08871
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Eribulin.
DB08912
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dabrafenib.
DB08936
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Chlorcyclizine.
DB08972
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Flumequine.
DB09488
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Acrivastine.
DB11408
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Famphur.
DB11443
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Orbifloxacin.
DB11448
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Phosmet.
DB11491
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Sarafloxacin.
DB11511
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Difloxacin.
DB11591
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Bilastine.
DB11614
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Rupatadine.
DB11742
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ebastine.
DB11774
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Pazufloxacin.
DB11891
The risk or severity of QTc prolongation can be increased when Esmolol is combined with CUDC-907.
DB11892
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Prulifloxacin.
DB11943
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Delafloxacin.
DB12231
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Temefos.
DB12645
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Givinostat.
DB13627
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Oxolinic acid.
DB13744
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Piromidic acid.
DB13772
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Rufloxacin.
DB13823
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Pipemidic acid.
DB14713
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Inotersen.
DB00188
The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Esmolol.
DB00714
The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Esmolol.
DB00753
The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Esmolol.
DB00818
The risk or severity of QTc prolongation can be increased when Propofol is combined with Esmolol.
DB01189
The risk or severity of QTc prolongation can be increased when Desflurane is combined with Esmolol.
DB01236
The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Esmolol.
DB01623
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Thiothixene.
DB01167
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Itraconazole.
DB01071
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Mequitazine.
DB01601
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Lopinavir.
DB00344
The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Esmolol.
DB00845
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Clofazimine.
DB11796
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Fostemsavir.
DB00751
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Epinastine.
DB11853
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Relugolix.
DB00761
Esmolol may increase the hyperkalemic activities of Potassium chloride.
DB09125
Esmolol may increase the hyperkalemic activities of Potassium citrate.
DB11098
Esmolol may increase the hyperkalemic activities of Potassium bicarbonate.
DB14498
Esmolol may increase the hyperkalemic activities of Potassium acetate.
DB09087
Potassium alum may increase the hyperkalemic activities of Esmolol.
DB09413
Monopotassium phosphate may increase the hyperkalemic activities of Esmolol.
DB09414
Dipotassium phosphate may increase the hyperkalemic activities of Esmolol.
DB09449
Sodium phosphate, monobasic may increase the hyperkalemic activities of Esmolol.
DB09483
Potassium lactate may increase the hyperkalemic activities of Esmolol.
DB11090
Potassium nitrate may increase the hyperkalemic activities of Esmolol.
DB11107
Potassium bitartrate may increase the hyperkalemic activities of Esmolol.
DB11153
Potassium hydroxide may increase the hyperkalemic activities of Esmolol.
DB13620
Potassium gluconate may increase the hyperkalemic activities of Esmolol.
DB13735
Potassium guaiacolsulfonate may increase the hyperkalemic activities of Esmolol.
DB13831
Potassium permanganate may increase the hyperkalemic activities of Esmolol.
DB13977
Potassium carbonate may increase the hyperkalemic activities of Esmolol.
DB14492
Potassium triiodide may increase the hyperkalemic activities of Esmolol.
DB14499
Potassium sulfate may increase the hyperkalemic activities of Esmolol.
DB14500
Potassium may increase the hyperkalemic activities of Esmolol.
DB06715
Potassium Iodide may increase the hyperkalemic activities of Esmolol.
DB09418
Potassium perchlorate may increase the hyperkalemic activities of Esmolol.
DB01345
Esmolol may increase the hyperkalemic activities of Potassium cation.
DB09061
The metabolism of Esmolol can be decreased when combined with Cannabidiol.
DB00208
The metabolism of Esmolol can be decreased when combined with Ticlopidine.
DB00333
The metabolism of Esmolol can be decreased when combined with Methadone.
DB00398
The metabolism of Esmolol can be decreased when combined with Sorafenib.
DB00412
The metabolism of Esmolol can be decreased when combined with Rosiglitazone.
DB00439
The metabolism of Esmolol can be decreased when combined with Cerivastatin.
DB00574
The metabolism of Esmolol can be decreased when combined with Fenfluramine.
DB00647
The metabolism of Esmolol can be decreased when combined with Dextropropoxyphene.
DB00792
The metabolism of Esmolol can be decreased when combined with Tripelennamine.
DB00810
The metabolism of Esmolol can be decreased when combined with Biperiden.
DB00997
The metabolism of Esmolol can be decreased when combined with Doxorubicin.
DB01005
The metabolism of Esmolol can be decreased when combined with Hydroxyurea.
DB01075
The metabolism of Esmolol can be decreased when combined with Diphenhydramine.
DB01110
The metabolism of Esmolol can be decreased when combined with Miconazole.
DB01128
The metabolism of Esmolol can be decreased when combined with Bicalutamide.
DB01233
The metabolism of Esmolol can be decreased when combined with Metoclopramide.
DB05271
The metabolism of Esmolol can be decreased when combined with Rotigotine.
DB06204
The metabolism of Esmolol can be decreased when combined with Tapentadol.
DB06370
The metabolism of Esmolol can be decreased when combined with Indisulam.
DB06412
The metabolism of Esmolol can be decreased when combined with Oxymetholone.
DB08864
The metabolism of Esmolol can be decreased when combined with Rilpivirine.
DB09049
The metabolism of Esmolol can be decreased when combined with Naloxegol.
DB09118
The metabolism of Esmolol can be decreased when combined with Stiripentol.
DB11633
The metabolism of Esmolol can be decreased when combined with Isavuconazole.
DB11638
The metabolism of Esmolol can be decreased when combined with Artenimol.
DB11994
The metabolism of Esmolol can be decreased when combined with Diacerein.
DB12245
The metabolism of Esmolol can be decreased when combined with Triclabendazole.
DB13975
The metabolism of Esmolol can be decreased when combined with Black cohosh.
DB01062
The metabolism of Esmolol can be decreased when combined with Oxybutynin.
DB01093
The metabolism of Esmolol can be decreased when combined with Dimethyl sulfoxide.
DB00972
The metabolism of Esmolol can be decreased when combined with Azelastine.
DB00220
The metabolism of Esmolol can be decreased when combined with Nelfinavir.
DB06691
The metabolism of Esmolol can be decreased when combined with Mepyramine.
DB01096
The metabolism of Esmolol can be decreased when combined with Oxamniquine.
DB01562
The metabolism of Esmolol can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
DB14009
The metabolism of Esmolol can be decreased when combined with Medical Cannabis.
DB14011
The metabolism of Esmolol can be decreased when combined with Nabiximols.
DB14635
The metabolism of Esmolol can be decreased when combined with Curcumin sulfate.
DB01590
The metabolism of Esmolol can be decreased when combined with Everolimus.
DB00863
The metabolism of Esmolol can be decreased when combined with Ranitidine.
DB00627
The metabolism of Esmolol can be decreased when combined with Niacin.
DB01142
The metabolism of Esmolol can be decreased when combined with Doxepin.
DB12500
The metabolism of Esmolol can be decreased when combined with Fedratinib.
DB00022
The metabolism of Esmolol can be decreased when combined with Peginterferon alfa-2b.
DB00209
The metabolism of Esmolol can be decreased when combined with Trospium.
DB00227
The metabolism of Esmolol can be decreased when combined with Lovastatin.
DB00234
The metabolism of Esmolol can be decreased when combined with Reboxetine.
DB00238
The metabolism of Esmolol can be decreased when combined with Nevirapine.
DB00317
The metabolism of Esmolol can be decreased when combined with Gefitinib.
DB00338
The metabolism of Esmolol can be decreased when combined with Omeprazole.
DB00361
The metabolism of Esmolol can be decreased when combined with Vinorelbine.
DB00448
The metabolism of Esmolol can be decreased when combined with Lansoprazole.
DB00494
The metabolism of Esmolol can be decreased when combined with Entacapone.
DB00570
The metabolism of Esmolol can be decreased when combined with Vinblastine.
DB00921
The metabolism of Esmolol can be decreased when combined with Buprenorphine.
DB01129
The metabolism of Esmolol can be decreased when combined with Rabeprazole.
DB01131
The metabolism of Esmolol can be decreased when combined with Proguanil.
DB01191
The metabolism of Esmolol can be decreased when combined with Dexfenfluramine.
DB01323
The metabolism of Esmolol can be decreased when combined with St. John's Wort.
DB04938
The metabolism of Esmolol can be decreased when combined with Ospemifene.
DB06287
The metabolism of Esmolol can be decreased when combined with Temsirolimus.
DB06512
The metabolism of Esmolol can be decreased when combined with Deramciclane.
DB09065
The metabolism of Esmolol can be decreased when combined with Cobicistat.
DB11837
The metabolism of Esmolol can be decreased when combined with Osilodrostat.
DB04911
The metabolism of Esmolol can be decreased when combined with Oritavancin.
DB00193
The metabolism of Tramadol can be decreased when combined with Esmolol.
DB00216
The metabolism of Eletriptan can be decreased when combined with Esmolol.
DB00316
The metabolism of Acetaminophen can be decreased when combined with Esmolol.
DB00318
The metabolism of Codeine can be decreased when combined with Esmolol.
DB00356
The metabolism of Chlorzoxazone can be decreased when combined with Esmolol.
DB00377
The metabolism of Palonosetron can be decreased when combined with Esmolol.
DB00396
The metabolism of Progesterone can be decreased when combined with Esmolol.
DB00409
The metabolism of Remoxipride can be decreased when combined with Esmolol.
DB00425
The metabolism of Zolpidem can be decreased when combined with Esmolol.
DB00490
The metabolism of Buspirone can be decreased when combined with Esmolol.
DB00497
The metabolism of Oxycodone can be decreased when combined with Esmolol.
DB00514
The metabolism of Dextromethorphan can be decreased when combined with Esmolol.
DB00592
The metabolism of Piperazine can be decreased when combined with Esmolol.
DB00641
The metabolism of Simvastatin can be decreased when combined with Esmolol.
DB00701
The metabolism of Amprenavir can be decreased when combined with Esmolol.
DB00731
The metabolism of Nateglinide can be decreased when combined with Esmolol.
DB00737
The metabolism of Meclizine can be decreased when combined with Esmolol.
DB00914
The metabolism of Phenformin can be decreased when combined with Esmolol.
DB00918
The metabolism of Almotriptan can be decreased when combined with Esmolol.
DB01028
The metabolism of Methoxyflurane can be decreased when combined with Esmolol.
DB01095
The metabolism of Fluvastatin can be decreased when combined with Esmolol.
DB01177
The metabolism of Idarubicin can be decreased when combined with Esmolol.
DB01192
The metabolism of Oxymorphone can be decreased when combined with Esmolol.
DB01409
The metabolism of Tiotropium can be decreased when combined with Esmolol.
DB01466
The metabolism of Ethylmorphine can be decreased when combined with Esmolol.
DB01551
The metabolism of Dihydrocodeine can be decreased when combined with Esmolol.
DB03783
The metabolism of Phenacetin can be decreased when combined with Esmolol.
DB04905
The metabolism of Tesmilifene can be decreased when combined with Esmolol.
DB06016
The metabolism of Cariprazine can be decreased when combined with Esmolol.
DB06144
The metabolism of Sertindole can be decreased when combined with Esmolol.
DB06148
The metabolism of Mianserin can be decreased when combined with Esmolol.
DB06203
The metabolism of Alogliptin can be decreased when combined with Esmolol.
DB06506
The metabolism of Repinotan can be decreased when combined with Esmolol.
DB06608
The metabolism of Tafenoquine can be decreased when combined with Esmolol.
DB06678
The metabolism of Esmirtazapine can be decreased when combined with Esmolol.
DB06702
The metabolism of Fesoterodine can be decreased when combined with Esmolol.
DB06735
The metabolism of Enclomiphene can be decreased when combined with Esmolol.
DB06770
The metabolism of Benzyl alcohol can be decreased when combined with Esmolol.
DB08922
The metabolism of Perospirone can be decreased when combined with Esmolol.
DB09048
The metabolism of Netupitant can be decreased when combined with Esmolol.
DB09053
The metabolism of Ibrutinib can be decreased when combined with Esmolol.
DB09068
The metabolism of Vortioxetine can be decreased when combined with Esmolol.
DB09076
The metabolism of Umeclidinium can be decreased when combined with Esmolol.
DB09183
The metabolism of Dasabuvir can be decreased when combined with Esmolol.
DB09195
The metabolism of Lorpiprazole can be decreased when combined with Esmolol.
DB11130
The metabolism of Opium can be decreased when combined with Esmolol.
DB11855
The metabolism of Revefenacin can be decreased when combined with Esmolol.
DB11915
The metabolism of Valbenazine can be decreased when combined with Esmolol.
DB11979
The metabolism of Elagolix can be decreased when combined with Esmolol.
DB12070
The metabolism of Letermovir can be decreased when combined with Esmolol.
DB13293
The metabolism of Ipecac can be decreased when combined with Esmolol.
DB09173
The metabolism of Butyrfentanyl can be decreased when combined with Esmolol.
DB11757
The metabolism of Istradefylline can be decreased when combined with Esmolol.
DB01410
The metabolism of Ciclesonide can be decreased when combined with Esmolol.
DB04889
The metabolism of Bicifadine can be decreased when combined with Esmolol.
DB00252
The metabolism of Phenytoin can be decreased when combined with Esmolol.
DB00454
The metabolism of Meperidine can be decreased when combined with Esmolol.
DB00532
The metabolism of Mephenytoin can be decreased when combined with Esmolol.
DB14881
The metabolism of Oliceridine can be decreased when combined with Esmolol.
DB00530
The metabolism of Erlotinib can be decreased when combined with Esmolol.
DB00637
The metabolism of Astemizole can be decreased when combined with Esmolol.
DB11963
The metabolism of Esmolol can be decreased when combined with Dacomitinib.
DB00675
The metabolism of Esmolol can be decreased when combined with Tamoxifen.
DB13874
The metabolism of Esmolol can be decreased when combined with Enasidenib.
DB05109
The metabolism of Trabectedin can be decreased when combined with Esmolol.
DB08901
The metabolism of Ponatinib can be decreased when combined with Esmolol.
DB00277
The metabolism of Theophylline can be decreased when combined with Esmolol.
DB01100
The metabolism of Pimozide can be decreased when combined with Esmolol.
DB00321
The metabolism of Esmolol can be decreased when combined with Amitriptyline.
DB00540
The metabolism of Esmolol can be decreased when combined with Nortriptyline.
DB00543
The metabolism of Esmolol can be decreased when combined with Amoxapine.
DB00726
The metabolism of Esmolol can be decreased when combined with Trimipramine.
DB01242
The metabolism of Esmolol can be decreased when combined with Clomipramine.
DB00181
The risk or severity of adverse effects can be increased when Baclofen is combined with Esmolol.
DB00258
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium acetate.
DB00326
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium glucoheptonate.
DB01164
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium chloride.
DB01373
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium.
DB06724
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium carbonate.
DB11093
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium citrate.
DB11126
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium gluconate.
DB11348
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium Phosphate.
DB13142
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium glubionate anhydrous.
DB13231
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium lactate.
DB13365
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium lactate gluconate.
DB13590
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium pangamate.
DB13800
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium levulinate.
DB14577
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium cation.
DB14684
The therapeutic efficacy of Esmolol can be decreased when used in combination with Calcium polycarbophil.
DB13917
The therapeutic efficacy of Esmolol can be increased when used in combination with Deoxyepinephrine.
DB00005
The metabolism of Esmolol can be increased when combined with Etanercept.
DB00026
The metabolism of Esmolol can be increased when combined with Anakinra.
DB00051
The metabolism of Esmolol can be increased when combined with Adalimumab.
DB00065
The metabolism of Esmolol can be increased when combined with Infliximab.
DB01281
The metabolism of Esmolol can be increased when combined with Abatacept.
DB04956
The metabolism of Esmolol can be increased when combined with Afelimomab.
DB05676
The metabolism of Esmolol can be increased when combined with Apremilast.
DB06168
The metabolism of Esmolol can be increased when combined with Canakinumab.
DB06273
The metabolism of Esmolol can be increased when combined with Tocilizumab.
DB06372
The metabolism of Esmolol can be increased when combined with Rilonacept.
DB06674
The metabolism of Esmolol can be increased when combined with Golimumab.
DB08904
The metabolism of Esmolol can be increased when combined with Certolizumab pegol.
DB09029
The metabolism of Esmolol can be increased when combined with Secukinumab.
DB09036
The metabolism of Esmolol can be increased when combined with Siltuximab.
DB14724
The metabolism of Esmolol can be increased when combined with Emapalumab.
DB00182
The therapeutic efficacy of Esmolol can be decreased when used in combination with Amphetamine.
DB00191
The therapeutic efficacy of Esmolol can be decreased when used in combination with Phentermine.
DB00852
The therapeutic efficacy of Esmolol can be decreased when used in combination with Pseudoephedrine.
DB00865
The therapeutic efficacy of Esmolol can be decreased when used in combination with Benzphetamine.
DB00937
The therapeutic efficacy of Esmolol can be decreased when used in combination with Diethylpropion.
DB01255
The therapeutic efficacy of Esmolol can be decreased when used in combination with Lisdexamfetamine.
DB01365
The therapeutic efficacy of Esmolol can be decreased when used in combination with Mephentermine.
DB01442
The therapeutic efficacy of Esmolol can be decreased when used in combination with MMDA.
DB01454
The therapeutic efficacy of Esmolol can be decreased when used in combination with Midomafetamine.
DB01467
The therapeutic efficacy of Esmolol can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.
DB01484
The therapeutic efficacy of Esmolol can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.
DB01509
The therapeutic efficacy of Esmolol can be decreased when used in combination with Tenamfetamine.
DB01556
The therapeutic efficacy of Esmolol can be decreased when used in combination with Chlorphentermine.
DB01566
The therapeutic efficacy of Esmolol can be decreased when used in combination with Methylenedioxyethamphetamine.
DB01576
The therapeutic efficacy of Esmolol can be decreased when used in combination with Dextroamphetamine.
DB01577
The therapeutic efficacy of Esmolol can be decreased when used in combination with Metamfetamine.
DB09480
The therapeutic efficacy of Esmolol can be decreased when used in combination with Iofetamine I-123.
DB12080
The therapeutic efficacy of Esmolol can be decreased when used in combination with Ritobegron.
DB13108
The therapeutic efficacy of Esmolol can be decreased when used in combination with Mephedrone.
DB13624
The therapeutic efficacy of Esmolol can be decreased when used in combination with Methoxyphenamine.
DB13703
The therapeutic efficacy of Esmolol can be decreased when used in combination with Gepefrine.
DB13940
The therapeutic efficacy of Esmolol can be decreased when used in combination with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB00190
The risk or severity of hypotension can be increased when Carbidopa is combined with Esmolol.
DB00228
Enflurane may increase the cardiodepressant activities of Esmolol.
DB00024
The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Esmolol.
DB00279
The therapeutic efficacy of Liothyronine can be decreased when used in combination with Esmolol.
DB00451
The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Esmolol.
DB01583
The therapeutic efficacy of Liotrix can be decreased when used in combination with Esmolol.
DB03604
The therapeutic efficacy of Tiratricol can be decreased when used in combination with Esmolol.
DB09100
The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Esmolol.
DB00457
The risk or severity of hypotension can be increased when Prazosin is combined with Esmolol.
DB01238
The risk or severity of hypotension can be increased when Aripiprazole is combined with Esmolol.
DB14185
The risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Esmolol.
DB00373
The risk or severity of adverse effects can be increased when Timolol is combined with Esmolol.
DB00612
The risk or severity of adverse effects can be increased when Bisoprolol is combined with Esmolol.
DB00575
The risk or severity of hypotension can be increased when Clonidine is combined with Esmolol.
DB00656
The risk or severity of QTc prolongation can be increased when Trazodone is combined with Esmolol.
DB00040
The therapeutic efficacy of Esmolol can be decreased when used in combination with Glucagon.
DB11986
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Entrectinib.
DB11642
Pitolisant may increase the QTc-prolonging activities of Esmolol.
DB12825
Lefamulin may increase the QTc-prolonging activities of Esmolol.
DB00763
The excretion of Esmolol can be decreased when combined with Methimazole.
DB01175
The serum concentration of Escitalopram can be increased when it is combined with Esmolol.
DB01224
Esmolol may increase the hypotensive activities of Quetiapine.
DB11732
Lasmiditan may increase the bradycardic activities of Esmolol.
DB15066
The serum concentration of Esmolol can be increased when it is combined with Givosiran.
DB00661
The risk or severity of adverse effects can be increased when Esmolol is combined with Verapamil.
DB00243
The serum concentration of Esmolol can be increased when it is combined with Ranolazine.
DB00557
The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Esmolol.
DB00246
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ziprasidone.
DB00436
The therapeutic efficacy of Bendroflumethiazide can be increased when used in combination with Esmolol.
DB00606
The therapeutic efficacy of Cyclothiazide can be increased when used in combination with Esmolol.
DB00774
The therapeutic efficacy of Hydroflumethiazide can be increased when used in combination with Esmolol.
DB00880
The therapeutic efficacy of Chlorothiazide can be increased when used in combination with Esmolol.
DB00999
The therapeutic efficacy of Hydrochlorothiazide can be increased when used in combination with Esmolol.
DB01021
The therapeutic efficacy of Trichlormethiazide can be increased when used in combination with Esmolol.
DB01324
The therapeutic efficacy of Polythiazide can be increased when used in combination with Esmolol.
DB13532
The therapeutic efficacy of Cyclopenthiazide can be increased when used in combination with Esmolol.
DB00232
The therapeutic efficacy of Esmolol can be increased when used in combination with Methyclothiazide.
DB00562
The therapeutic efficacy of Esmolol can be increased when used in combination with Benzthiazide.
DB13430
The therapeutic efficacy of Esmolol can be increased when used in combination with Mebutizide.
DB00502
The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Esmolol.
DB00472
The serum concentration of Esmolol can be increased when it is combined with Fluoxetine.
DB00808
The therapeutic efficacy of Indapamide can be increased when used in combination with Esmolol.
DB00104
The serum concentration of the active metabolites of Esmolol can be increased when Esmolol is used in combination with Octreotide.

序列

实验性质

Water Solubility
Very soluble as hydrochloride salt

logP
1.7

外部标识符

resource：Drugs Product Database (DPD)
identifier：20260
resource：ChEBI
identifier：88206
resource：PubChem Compound
identifier：59768
resource：PubChem Substance
identifier：46506146
resource：KEGG Compound
identifier：C06980
resource：KEGG Drug
identifier：D07916
resource：ChemSpider
identifier：53916
resource：BindingDB
identifier：50404796
resource：PharmGKB
identifier：PA449500
resource：Therapeutic Targets Database
identifier：DAP000304
resource：Wikipedia
identifier：Esmolol
resource：ChEMBL
identifier：CHEMBL768
resource：RxCUI
identifier：49737

外部链接

RxList
http://www.rxlist.com/cgi/generic3/esmolol.htm
Drugs.com
http://www.drugs.com/cdi/esmolol.html

路径

smpdb-id:SMP0000301
name:Esmolol Action Pathway
category:drug_action
drugbank-id:DB00171
name:ATP
drugbank-id:DB00187
name:Esmolol
drugbank-id:DB01345
name:Potassium cation
drugbank-id:DB01373
name:Calcium
drugbank-id:DB01378
name:Magnesium cation
enzymes_uniprot-id:P08588
enzymes_uniprot-id:P05023
enzymes_uniprot-id:P50993
enzymes_uniprot-id:P13637
enzymes_uniprot-id:Q13733
enzymes_uniprot-id:P05026
enzymes_uniprot-id:P14415
enzymes_uniprot-id:P54709
enzymes_uniprot-id:B7ZKV8
enzymes_uniprot-id:P54710
enzymes_uniprot-id:P63252
enzymes_uniprot-id:P48050
enzymes_uniprot-id:P48549
enzymes_uniprot-id:P48544
enzymes_uniprot-id:Q9UK17
enzymes_uniprot-id:Q9NS61
enzymes_uniprot-id:P22460
enzymes_uniprot-id:Q12959
enzymes_uniprot-id:P51787
enzymes_uniprot-id:P15382
enzymes_uniprot-id:Q9Y6J6
enzymes_uniprot-id:Q12809
enzymes_uniprot-id:Q5I7T1
enzymes_uniprot-id:Q09428
enzymes_uniprot-id:Q15842
enzymes_uniprot-id:Q14654
enzymes_uniprot-id:O60706
enzymes_uniprot-id:O00180
enzymes_uniprot-id:P32418
enzymes_uniprot-id:Q9Y3Q4
enzymes_uniprot-id:Q14524
enzymes_uniprot-id:Q13425
enzymes_uniprot-id:Q13884
enzymes_uniprot-id:Q13424
enzymes_uniprot-id:Q13936
enzymes_uniprot-id:Q9NY47
enzymes_uniprot-id:Q02641
enzymes_uniprot-id:P08172
enzymes_uniprot-id:Q92736
enzymes_uniprot-id:P16615
enzymes_uniprot-id:P26678
enzymes_uniprot-id:P17612
enzymes_uniprot-id:P10644
enzymes_uniprot-id:P62158
enzymes_uniprot-id:Q15746
enzymes_uniprot-id:P30556
enzymes_uniprot-id:Q9NQ66
enzymes_uniprot-id:P02585
enzymes_uniprot-id:P19237
enzymes_uniprot-id:P13805
enzymes_uniprot-id:P63316
enzymes_uniprot-id:P19429
enzymes_uniprot-id:P45379
enzymes_uniprot-id:P48788
enzymes_uniprot-id:P45378
enzymes_uniprot-id:P09493
enzymes_uniprot-id:P07951
enzymes_uniprot-id:O95180
enzymes_uniprot-id:O43497
enzymes_uniprot-id:Q14643

目标

id:BE0000172
name:Beta-1 adrenergic receptor
organism:Humans
action:antagonist
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
Jahn P, Eckrich B, Schneidrowski B, Volz-Zang C, Schulte B, Mutschler E, Palm D: Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor. Arzneimittelforschung. 1995 May;45(5):536-41.
Volz-Zang C, Eckrich B, Jahn P, Schneidrowski B, Schulte B, Palm D: Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties. Eur J Clin Pharmacol. 1994;46(5):399-404.
Kirshenbaum JM: Nonthrombolytic intervention in acute myocardial infarction. Am J Cardiol. 1989 Jul 18;64(4):25B-28B.
Jacobs JR, Maier GW, Rankin JS, Reves JG: Esmolol and left ventricular function in the awake dog. Anesthesiology. 1988 Mar;68(3):373-8.
Howie MB, Black HA, Zvara D, McSweeney TD, Martin DJ, Coffman JA: Esmolol reduces autonomic hypersensitivity and length of seizures induced by electroconvulsive therapy. Anesth Analg. 1990 Oct;71(4):384-8.
known-action:yes
name:Beta-1 adrenergic receptor
general-function:Receptor signaling protein activity
specific-function:Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
gene-name:ADRB1
locus:10q24-q26
cellular-location:Cell membrane
transmembrane-regions:56-84 94-120 133-154 173-196 223-248 320-349 355-377
signal-regions:
theoretical-pi:9.03
molecular-weight:51322.1
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:285GenAtlasADRB1GenBank Gene DatabaseJ03019GenBank Protein Database178200IUPHAR28Guide to Pharmacology28UniProtKBP08588UniProt AccessionADRB1_HUMAN
synonyms:ADRB1RB1ARBeta-1 adrenoceptorBeta-1 adrenoreceptor
amino-acid-sequence:>lcl|BSEQ0010188|Beta-1 adrenergic receptor MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAG MGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVV WGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVC TVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM AFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAP LANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFV FFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRRHATHGDRPRASGCLARPGP PPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV
gene-sequence:>lcl|BSEQ0010189|Beta-1 adrenergic receptor (ADRB1) ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAG AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC TCGAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGTAG
pfams:PF000017tm_1
go-classifiers:componentearly endosomecomponentintegral component of plasma membranecomponentplasma membranefunctionalpha-2A adrenergic receptor bindingfunctionbeta-adrenergic receptor activityfunctionbeta1-adrenergic receptor activityfunctionepinephrine bindingfunctionnorepinephrine bindingfunctionPDZ domain bindingfunctionprotein heterodimerization activityfunctionRas guanyl-nucleotide exchange factor activityfunctionreceptor signaling protein activityprocessactivation of adenylate cyclase activityprocessadenylate cyclase-activating adrenergic receptor signaling pathwayprocessbrown fat cell differentiationprocesscell-cell signalingprocessdiet induced thermogenesisprocessfear responseprocessheat generationprocessintracellular signal transductionprocessnegative regulation of multicellular organism growthprocesspositive regulation of cAMP biosynthetic processprocesspositive regulation of cAMP-mediated signalingprocesspositive regulation of GTPase activityprocesspositive regulation of heart rate by epinephrine-norepinephrineprocesspositive regulation of the force of heart contraction by epinephrine-norepinephrineprocessresponse to coldprocesstemperature homeostasisprocessvasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure

酶

BE0002363Cytochrome P450 2D6HumanssubstrateA3633417125412Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):981-1007. doi: 10.1517/17425255.2.6.981 .A1615514732961Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22.A3633327836712Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. doi: 10.1016/j.dmpk.2016.08.007. Epub 2016 Sep 2.noCytochrome P450 2D6Steroid hydroxylase activityResponsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.CYP2D622q13.1Endoplasmic reticulum membrane7.2655768.9422HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2625GenAtlasCYP2D6GenBank Gene DatabaseM20403GenBank Protein Database181350Guide to Pharmacology1329UniProtKBP10635UniProt AccessionCP2D6_HUMAN1.14.14.1Cholesterol 25-hydroxylaseCYP2DL1CYPIID6Cytochrome P450-DB1Debrisoquine 4-hydroxylase>lcl|BSEQ0004641|Cytochrome P450 2D6 MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV FAFLVSPSPYELCAVPR>lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6) ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG GACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG CCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG TTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG CTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC CGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC CTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC AACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT TGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA GCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT CGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG CGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC CTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG ACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG AAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT GACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC ATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG CAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT CATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA TCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC CTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC CGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG CTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC TTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAGPF00067p450componentcytoplasmcomponentendoplasmic reticulumcomponentendoplasmic reticulum membranecomponentmitochondrionfunctionarachidonic acid epoxygenase activityfunctionaromatase activityfunctiondrug bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenfunctionoxygen bindingfunctionsteroid hydroxylase activityprocessalkaloid catabolic processprocessalkaloid metabolic processprocessarachidonic acid metabolic processprocesscoumarin metabolic processprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocessisoquinoline alkaloid metabolic processprocessmonoterpenoid metabolic processprocessnegative regulation of bindingprocessnegative regulation of cellular organofluorine metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid metabolic processprocessxenobiotic metabolic process

载体

运输工具

药物反应

reactions:1
left-element--drugbank-id:DB00187
left-element--name:Esmolol
right-element--drugbank-id:DBMET00536
right-element--name:Methanol

效应

不良反应